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1. Introduction
Pituitary adenomas (PA) are frequent and typically benign endocrine neoplasia, which clinical
prevalence is estimated around 1/1000 inhabitants [1]. The vast majority are sporadic. PA are
endowed with significant clinical morbidity related to hormonal hypersecretion, neurological
symptoms due to intracranial mass effects or invasion of the surrounding structures and/or
secondary hypopituitarism. Their evolution is quite variable, ranging from indolent tumours
with an extremely slow growing potential, to recurrent, aggressive, and exceptionally
malignant tumours. Their current clinical management is based on pharmacological treatment,
mainly dopamine-agonists (DA) and somatostatin analogues (SSA), surgery and radiotherapy
[2]. Despite considerable progress in the management of PA, a significant subset of patients
are not satisfactorily controlled. Long-term uncontrolled pituitary hormone hypersecretion,
leading to potential severe systemic diseases, and tumour recurrence or aggressiveness still
represent a difficult clinical challenge. Understanding the mechanisms involved in the
pathogenesis of PA is essential for the development of new therapeutic strategies. In this
chapter, we will summarize current concepts in pituitary tumorigenesis and focus our
attention on the most recent insights and new perspectives in this field.
2. Pituitary tumours
Primary pituitary tumours in human are mainly represented by PA arising from endocrine
cells in the anterior lobe and craniopharyngiomas. These latter are divided into adamanti‐
nomatous, which derive from the Rathke’s pouch, and papillary craniopharyngiomas.
© 2013 Jaffrain-Rea et al.; licensee InTech. This is an open access article distributed under the terms of the
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Additional tumour types deriving from non-endocrine cells of the anterior pituitary and the
neurophypohysis can be found [3], which pathogenesis is poorly known and will not be
considered in this review.
2.1. Classification
PA may be classified according to their macroscopic characteristics into micro- (< 1 cm) or
macro-adenomas (≥ 1 cm), and enclosed or invasive adenomas. Invasion of the surround‐
ing structures (cavernous sinuses, bone, sphenoidal sinus) is generally defined according
to neuroradiological  imaging – especially magnetic  resonance imaging -,  although intra-
operative  findings  may  introduce  some  correction  to  the  pre-operative  radiological
classification or reveal macroscopic dural invasion. Of note, microscopic evidence of dural
invasion is rarely present on surgical samples. The functional classification of PA is based
on their hormone-secreting potential, which may be associated with bio-clinical evidence
of  hormone  hypersecretion  or  recognized  by  immunohistochemistry  (IHC)  for  pituitary
hormones  and/or  by  specific  ultrastructural  features.  From  an  epidemiological  point  of
view,  prolactinomas  are  by  far  the  most  frequent  (50-60%),  followed by  clinically  non-
functioning  PA  (NFPA)  (20-30%),  somatotrophinomas  (10-15%),  corticotrophinomas
(5-10%)  and  thyreotrophinomas  (1-2%)  [1,2,4].  Recruitment  bias  are  frequently  encoun‐
tered  in  pathological  series,  since  most  prolactinomas  are  treated  by  DA only.  Clinico-
pathological correlations in PA have been recently reviewed [4].  In the large majority of
PA associated with bio-clinical evidence of hormone secretion, except functional hyperpro‐
lactinemia, pathological examination will confirm the diagnosis of PRL, GH, ACTH or TSH-
secreting  tumours  and  potentially  identify  bi-  or  multi-hormonal  secretion.  This  is
especially true for GH-secreting PA, which may also secrete PRL, less frequently glycopro‐
tein hormones, or both (multihormonal). TSH-secreting adenomas are rare and frequently
multihormonal. Ultrastructural studies of secreting PA may disclose a “densely granulated”
(DG) or “sparsely granulated” (SG) pattern, which may reflect significant differences in
hormone secretion and tumour behaviour. This has been well studied in somatotrophino‐
mas,  where  IHC  for  cytokeratin  can  be  used  to  disclose  the  typical  “dot-like”  staining
pattern of SG adenomas. Although a continuum exists between the SG and DG types, pure
SG are typically more aggressive than DG somatotrophinomas [5]. Pathological examina‐
tion of  NFPA may show negative immunostaining for all  pituitary hormones (the “null
cell”  or  endocrine  inactive  histotype),  positive  immunostaining  for  FSH  and/or  LH
(gonadotrophinomas) or reveal silent secretion of other pituitary hormones, in particular
ACTH and GH (“silent” secreting PA). Cell lineage may also be identified by the expres‐
sion of specific transcription factors (see “pituitary ontogenesis”) [4]. It is generally accepted
that most NFPA derive from the gonadotroph lineage, since data obtained from primary
cultures  or  molecular  analysis  of  these  tumours  frequently  reveal  a  silent  expression of
gonadotropins or their subunits, including α−subunit only. Also, transgenic mice overex‐
pressing SV40 under the control of the βFSH promoter develop gonadotroph hyperplasia
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and PA with  reduced gonadotropin immunoreactivity  and ultrastructural  characteristics
similar to human null cell PA [6]. Silent corticotroph adenomas are commonly aggressive
and different subtypes have been described. Pituitary carcinomas are strictly defined by
the presence  of  extra-pituitary  dissemination (see  “pituitary  carcinomas”).  Therefore,  no
diagnosis of pituitary carcinoma can be made on a surgical pituitary sample. Considera‐
ble  efforts  have  been  made  to  recognize  the  aggressive  potential  of  PA  according  to
pathological  criteria.  However,  mitoses  are  generally  rare  and  the  percentage  of  cells
immunopositive  for  the  Ki67 antigen (which is  expressed throughout  the  cell  cycle  and
detected with the MIB1 monoclonal antibody) is currently considered as the best marker
of  cell  proliferation.  A  Ki67  index  ≥3%  is  commonly  associated  with  invasiveness  [4],
although it can be reduced by pre-operative pharmacological treatment in secreting PA [7].
Immunostaining for  p53 is  also  frequently  associated with invasiveness  and is  typically
present in carcinomas [4].  For these reasons, the 2004 WHO conference has proposed to
define as “atypical adenomas” a subset of invasive PA characterized by Ki67 labelling ≥
3% and extensive p53 nuclear staining [8].  However, many criticisms remain and search
for reliable markers of aggressiveness or malignancy is going on. Gene expression profiling
comparing non-invasive adenomas with their invasive counterpart [9, 10] or with pituita‐
ry carcinomas [11] represents a promising approach.
2.2. Origin
The pathogenesis of PA is multifactorial. Traditionally, two theories have been proposed: the
primary pituitary origin, and the hypothalamic origin of PA or, more generally speaking, the
concept that PA may derive from abnormal pituitary regulation. Acromegaly or Cushing’s
disease resulting from ectopic secretion of GHRH or CRH by neuroendocrine tumours,
respectively, or estrogen-induced prolactinomas, represent the main evidence for the second
theory. However, the chief lesion in such conditions is hyperplasia, with PA developing in a
very minority of cases, whereas hyperplasia is exceptionally observed surrounding the
tumoral tissue in human PA. Although hyperplasia may be difficult to identify (reticulin
staining is not routinely proposed), there is accumulating evidence supporting the primary
pituitary origin of PA. Indeed, PA are essentially monoclonal in origin, and a number of genetic
abnormalities have been identified these tumours, which include somatic events and inherited
predisposition. The relatively low rate of recurrences following complete surgical removal of
enclosed PA, especially microadenomas, also favours a primary pituitary hypothesis. How‐
ever, polyclonality can also be observed on PA, and different clones may develop in a syn‐
chronous or delayed pattern, possibly accounting for tumour progression or regrowth [12]. A
unifying view is that pituitary tumorigenesis is a multistep and multifactorial process, which
includes early initiating genetic events, growth promotion by extracellular factors (including
the extracellular matrix, growth factors, cytokines, neuropeptides and peripheral hormones)
and additional genetic events contributing to a further progression of the tumour in terms of
invasiveness, recurrences and, exceptionally, metastasis [13,14].
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3. Pituitary developmental pathways and their potential alterations in
pituitary tumours
Because the expanding knowledge about the molecular mechanisms involved in pituitary
ontogenesis is providing new clues in the understanding of pituitary tumorigenesis, relevant
findings in this field will be summarized.
3.1. Ontogenesis of the pituitary gland
The anterior pituitary lobe (AP) derives from an invagination of the oral ectoderm forming the
Rathke’s pouch (RP), which cells proliferate and subsequently undergo progressive terminal
differentiation into the 5 adult pituitary cell types (corticotrophs; somatotrophs, lactotrophs,
gonadotrophs and thyreotrophs), whereas the posterior lobe (or neurohypophysis) derives
from a specialized region of the neuroectoderm, the infundibulum. The intermediate lobe also
arises from the RP and contains melanotrophs in rodents but is virtually absent in humans.
The molecular mechanisms of pituitary ontogenesis have been mainly studied in the mouse
and, in addition to genetic models which have contributed to elucidate the role of single
proteins [6], analysis of transcriptomes obtained from cDNA libraries in the developing
embryo represents a promising tool to identify new genes involved in this process [15,16].
Complex interactions between signalling molecules (in particular opposite signals coming
from the diencephalon and the ventral ectoderm) and pituitary transcriptions factors (TFs) are
involved and tightly regulated in a spatially and temporally organised manner. Extensive
reviews are available on this topic [17,18]. Genetic defects in pituitary TFs are responsible for
inherited abnormalities in pituitary development, spanning from syndromic diseases due to
defects in early factors (eg. Pitx2, Lhx3/4, Hesx1) to multiple pituitary hormone deficiency
(eg Prop-1, Pit-1) or single hormone deficiency (eg. Tpit) [16]. Noteworthy, some of these defects
are associated with transient pituitary hyperplasia. On the other hand, abnormal signalling
from developmental molecules such as FGFs, BMPs, and master developing pathways (Wnt
Hedgehog, Notch) is being increasingly recognized in PA. Table 1 summarizes the potential
involvement of developmental TFs and signalling molecules in PA. Overall, the expression of
TFs involved in the terminal differentiation of pituitary cells (eg. Pit-1, Tpit) is maintained in
functioning PA and may contribute to identify the original cell lineage in NFPA [4,19].
However, a phenotypic marker may not be fully specific, as reported for NeuroD1, which is
frequently expressed in NFPA in addition to corticotrophinomas [20]. Early to intermediate
pituitary TFs such as Hesx1, Pitx1 and PROP1 are expressed in the adult pituitary gland and
in all PA [21-23]. PROP1 represses Hesx1 expression while up-regulating that of Pit-1 and SF1
and Prop-1 transgenic mice develop different PA phenotypes, except corticotrophinomas [24].
Pitx2, which is required at different stages of pituitary development, is expressed in the normal
pituitary, in PRL- and TSH-secreting PA and selectively overexpressed in NFPA [22]. FOXL2
is also expressed in the adult pituitary and overexpressed in gonadotroph and NFPA [25].
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Gene Expression
during
ontogenesis
Function Expression in pituitary tumours
Early signalling molecules in pituitary development
BMPs
(BMP 2 and
4)
VD BMP4: essential for the invagination of Rathke’s pouch;
BMP2: involved in opposing gradients with FGF8 that
generate distinct patterns of transcription factors
expression
BMP4: overexpressed in prolactinomas,
underexpressed in corticotrophinomas
FGFs
(FGF 8 and
10)
VD/RP FGF10 : essential for cell survival
FGF8: involved in the maintenance of RP cells
proliferation opposing gradients with BMP2
NA
WNT4 and
5A/
β-catenin
VD/RP Involved in pituitary development and in the induction
of Pit-1
Wnt4 : expressed in GH/PRL/TSH-secreting
PA
Shh/Gli2 VD; oral ectoderm
except RP
Involved in early proliferation and cell type
determination as well as in the control of adult pituitary
cell function and proliferation
Shh: underexpressed in PA, including
corticotrophinomas
Notch 2 and
3
VD/RP Required for early lineage commitment and the terminal
differentiation of distinct cell lineages
Notch3: overexpressed in NFPA
Sox2 VD/RP Required for pituitary development and the
maintenance or proliferation of pituitary progenitor cells
Expressed in adamantinomatous
craniopharyngiomas
Transcriptional factors that control pituitary development
Hesx1 VD/RP Involved in early pituitary development Expressed in all PA phenotypes
Otx2 RP Involved in RP development, in particular in the
expression of Hesx1
NA
Lhx3-4 RP Required for cell survival and prevention of apoptosis NA
Isl1 RP Required for the proliferation and differentiation of
pituitary progenitors
NA
Six 1, 3 and
6
RP Six1 regulates cell proliferation; Six6 is required for
pituitary development and cell proliferation; Six3
interacts with Hesx1
NA
Pitx 1 and 2 RP Pitx1 e Pitx2 activate the early transcription of the αGSU
gene, while promoting cell proliferation, then they
Pitx1: expressed in all PA phenotypes
Pitx2: overexpressed in NFPA
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Gene Expression
during
ontogenesis
Function Expression in pituitary tumours
activate LHβ, FSHβ, GnRH, PRL and GH gene
transcription, while promoting cell differentiation
Pitx1 also binds the POMC promoter
FOXL2 AP A transcriptional activator of αGSU Overexpressed in NFPA
Corticotroph differentiation
NeuroD1 RP A transcriptional activator of POMC, involved in
corticotroph differentiation
Expressed in corticotrophinomas and a
subset of NFPA
Tpit POMC precursor A transcriptional activator of POMC, essential for the
specification and terminal differentiation of
corticotrophs and melanotrophs,
Expressed in secreting and silent
corticotrophinomas
Differentiation of Pit-1 lineages: somatotroph, lactotroph and thyreotroph differentiation
Prop1 RP A transcriptional activator of Pit-1 and a trascriptional
repressor of Hesx1
Expressed in all PA phenotypes
Gata2 RP Interacts and cooperates with Pit-1 for the activation of
TSHβ
Expressed essentially in gonadotroph and
thyreotroph PA
Pit-1 Pit-1 lineages Essential for the terminal differentiation and expansion
of GH/PRL/TSH-secreting cells; an enhancer of GH, PRL,
TSHβ e GHRHR gene expression and a repressor of Gata2
Expressed in GH/PRL/TSH-secreting PA
(including NFPA with silent secretion)
CREB Pit-1 lineages Required in somatotrophs Expressed in all somatotrophinomas
Gonadotroph differentiation
Gata2 RP/pituitary A promoter of SF1 gene expression See above
SF1 Gonadotrope A promoter of αGSU, FSHβ, GnRHR gene expression, it
also interacts with Egr1 and Pitx1 for the activation of
LHβ
Expressed in the majority of gonadotroph/
NFPA, not in GH/PRL-secreting PA
Egr1 Gonadotrope Required for LHβ gene expression NA
Table 1. Expression of pituitary developmental signalling molecules and TFs
3.2. Developmental pathways in pituitary adenomas
Three master developmental pathways – Wnt, Hedgehog and Notch – have been involved in
several human diseases, in particular in cancer. We will attempt to summarize current
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knowledge about their role in pituitary development and tumorigenesis, which is likely to
expand significantly in the next years.
3.2.1. The Wnt/beta-catenin pathway
The canonical Wnt/β-catenin signalling pathway plays a role in the specification of pituitary
progenitor/stem cells and β-catenin modulates the transcriptional activity of several pituitary
TFs, in particular Pitx2, PROP-1 (thereby promoting the activation of Pit-1 and the repression
of Hesx1) and SF1 [26]. Wnt4 and Wnt5a have been involved in pituitary development and
growth, respectively. Wnt signalling has also been recently involved in the pathogenesis of
craniopharyngiomas [27-30] and PA [26]. Briefly, secreted Wnt proteins bind the Frizzled (Fz)/
Lipoprotein low-density receptor (LPR) membrane complex on the cell surface of target cells,
inducing an intracellular reponse mediated by Dishevelled (Dsh), the glycogen synthase kinase
3β (GSK-3β), Adenomatous Polypous Coli (APC), axin and β-catenin. In the absence of Wnt
ligands, the GSK-3/APC/axin complex drives phosphorylated β–catenin to proteasome-
mediated degradation and Wnt signalling is repressed. In the presence of Wnt ligands, the
inhibition of β−catenin phosphorylation leads to its cytoplasmic accumulation, nuclear
localization and activation of Wnt target genes (eg cyclin D, c-myc, survivin). Wnt signalling is
modulated by several secreted Wnt inhibitors and further regulated by adhesion molecules
(eg. E-cadherin) and extra-cellular signalling pathways (eg. FGF). Beta-catenin mutants lacking
phosphorylation sites are able to activate Wnt signalling in a constitutive manner. Activating
mutations of the β–catenin gene (cadherin-associated protein β1/CTNNB1) have been reported in
several human neoplasias and in adamantinomatous craniopharyngiomas (ACPs) [27].
Although the prevalence of CTNNB1 mutations has been variably appreciated in craniophar‐
yngiomas, they are specific for the ACP phenotype and consist of amino acid substitution of
GSK-3β phosphorylation site or flanking residues [28, 29]. Their causative role in the devel‐
opment of ACPs has been recently proven in a transgenic mice model [30]. CTNNB1 mutations
are exceptional in PA, but several members of the Wnt signalling pathway have been detected
at a transcriptional level [26]. Studies on β-catenin expression and localization in PA have lead
to conflicting results, some studies reporting a nuclear accumulation in a variable proportion
of cases (0-57%) and others a predominant membrane staining with a frequent cytoplasmic
immunopositivity [26]. A reduced expression of several Wnt inhibitors has been reported in
PA [31]. Among them, WIF1 is a tumour suppressor, which reduced protein expression was
predominantly reported in NFPA, although transcriptional down-regulation is common in all
histotypes [31].
3.2.2. Sonic hedgehog
Sonic hedgehog (Shh) is involved in pituitary ontogenesis and regulates pituitary hormone
release. Shh signalling is mediated by Patched receptors (Ptc1, Ptc2) and the Gli family of TFs.
During ontogenesis, Shh is expressed by the ventral diencephalon and by the oral ectoderm
immediately adjacent to RP. There is recent evidence that Shh signalling is of particular
importance before the RP detachs from the oral ectoderm, and that Gli2 is responsible for the
proliferation of early pituitary progenitors and for the diencephalic induction of FGF8 and
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BMP4 [32]. This is consistent with reports of human inactivating Gli2 germline mutations
associated with severe pituitary developmental defects and different degrees of craniofacial
abnormalities [33]. In the adult pituitary Shh/Ptc2/Gli1 signalling is active in corticotrophs and
stimulates POMC transcription and ACTH release; Gli1 is necessary for CRF signalling [34].
Contrasting with the corticotroph specificity of Shh, Ptc receptors are also expressed in other
pituitary secreting cells, although in a phenotype-specific manner [34]. Shh immunostaining
was found low or absent in a large series of PA, including corticotrophinomas, whereas the
expression of Ptch receptors was retained [35]. Shh was also found to stimulate ACTH, GH
and PRL secretion by normal and tumorous pituitary cells in vitro and to inhibit cell prolifer‐
ation in pituitary cell lines [35]. Thus, Shh may exert differential effects on pituitary cell growth
(with stimulating effects on progenitor cells and inhibiting effects in differentiated cells) and
is able to differentially modulate secretion and proliferation in PA.
3.2.3. Notch/Hes1
Notch signalling regulates progenitor cell differentiation during embryogenesis. Notch is a
cell-to-cell signalling network composed by transmembrane ligands (in mammals Delta-like
1,3,4 and Jagged 1,2), the transmembrane Notch receptors (Notch 1-4), and a transcription
factor (in mammals RBPJ), which is activated by the intracellular fragment of Notch after
ligand-induced Notch cleavage has occurred. Notch target genes encode beta-helix loop-helix
(bHLH) TFs, in particular the Hairy Enhancer of Split (Hes) family. A peculiarity of Notch
signalling is lateral inhibition, with intracellular signalling being inactive in cells expressing
Notch ligands. After the Notch pathway was shown to be oncogenic in haematological
malignancies, it has been involved in several solid tumours, with either oncogenic or tumour
suppressing functions, depending on the tissue and the expression of the different components
of the Notch pathway. Notch is also involved in angiogenesis and participates in tumour
angiogenesis through interactions with the VEGF pathway [36]. Genes encoding Notch
signalling molecules are temporally and spatially regulated in the developing pituitary.
During rodent pituitary ontogenesis, expression of the Notch2, Notch 3 and Delta-like 1 (Dll1)
genes was observed in the RP, whereas Delta-like 3 (Dll3) gene expression was restricted to the
melanotrophs and early corticotrophs [37]. PROP-1 has been shown to specifically induce
Notch2, with Prop1 ablation inducing a dramatic reduction in Notch2 and a concomitant
increase in Dll1 [37]. Expression of the Hes1 and Hes6 genes was also observed in the RP [37].
HES1 was subsequently shown to repress the expression of different cell cycle inhibitors and
mediate the balance between pituitary progenitors proliferation and differentiation [38]. At
the moment, few data are available on the possible role of the Notch pathway in the pituitary
tumorigenesis. Overexpression of Notch3 has been recently reported in NFPA [39], and several
elements of the Notch pathways have been identified in the transcriptome of prolactinomas
[40] and multihormonal PA [41], suggesting that new data will be available in the future.
3.3. Pituitary stem cells
The pituitary gland is characterized by a high degree of plasticity, which is involved in
pituitary function changes through life and adaptation to physiological and pathological
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variations in peripheral hormone feed-back. Several conditions require a re-organization of
pituitary cell composition, with an expansion of a specific cell pool (eg. lactotrophs during
pregnancy and lactation). This may theoretically result from an increased proliferation of
already differentiated cells, a transdifferentiation from a pre-existing cell population or a
recruitment of putative adult pituitary stem/progenitor cells [42,43]. The presence of post-natal
pituitary progenitor/stem cells able to self-renew and differentiate into hormone-secreting cells
has now been recognized by several groups. Five potential pituitary stem cells or progenitor
cell populations have been characterized in the mouse and reported as side population (SP),
pituitary colony-forming cells, nestin-expressing cells, Sox2+/Sox9- cells and GFR-α2-Prop1-
Stem cell marker-expressing (GPS) cells, respectively [42,43]. The best characterized are SP
cells, Sox2+/Sox9- and GPS cells [42,43]. These cell populations represent <1% to 3-5% of anterior
pituitary cells, are localized mainly along the Rathke’s cleft (the proposed pituitary stem cells
niche) and are able to form pituispheres in vitro. The question arises whether these cells may
contribute to pituitary tumorigenesis. Cancer stem cells have been reported in a number of
human malignancies and derive their name from their ability to develop tumours, in the same
way by which normal stem cells lead to organ development. Their origin is not fully under‐
stood and they may derive from normal stem cells, re-differentiation/dedifferentiation of
progenitor or differentiated cells, or both [42]. A possible role for pituitary progenitor/stem
cells in pituitary tumorigenesis has been recently proposed. Conditional deletion of RB in Pax7
precursors was sufficient to generate NFPA in mice [44]. In addition, floating clonal spheres
have been isolated from two human PA [45]. These putative ‘pituitary adenoma stem-like cells’
(PASCs) overexpressed several stem cells-related genes, including components of the Notch
and Wnt/β-catenin pathways and were tumorigenic in vivo. Tumours from the mice cranio‐
pharyngioma model cited hitherto also contained cells with phenotypic characteristics of
progenitor/stem cells and Sox2/Sox9 expression [30]. Similar findings have been reported in
human ACP, with a subset of samples also expressing RET or GFRα [46]. Further work is
warranted to clarify the possible contribution of stem cells in PA, especially in those showing
an aggressive behavior.
4. Genetics of pituitary tumours
PA are triggered by a variety of genetic abnormalities [13,14,47]. The vast majority occur at a
somatic level, but inherited predisposition is being increasingly recognized.
4.1. Inherited predisposition to pituitary tumours
Although inherited predisposition to PAs is often recognized in a familial setting, a sporadic
presentation may occur. In addition to their implications for familial screening, genes involved
in hereditary tumours may provide important clues in the comprehension of the molecular
basis of tumorigenesis. We have recently reviewed this topic and proposed an algorithm for
genetic screening in patients with PA [48].
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4.1.1. Multiple Endocrine Neoplasia type 1 (MEN1)
MEN1 is an autosomal dominant condition defined by the presence, in a single subject or
within a single family, of two or more hyperplastic and/or adenomatous lesions of the
parathyroid glands (~90%), the gastro-entero-pancreatic (GEP) tract (30-80%) and/or the
anterior pituitary (~40%). The clinical characteristics of MEN1-related PA have been recently
reviewed elsewhere [48,49]. Briefly, their phenotypic distribution is unremarkable when
compared to sporadic PA, with a predominance of prolactinomas (~60%), but they are more
frequently invasive and resistant to pharmacological treatment. Pediatric onset is not uncom‐
mon, especially for PRL- and ACTH-secreting PA, and carcinomas have been reported. Peri-
tumoral hyperplasia is rare, but multiple and plurihormonal adenomas are more frequent than
in sporadic PA [50]. Since the identification of the MEN1 gene in 11q13, direct sequencing has
been developed in many laboratories worldwide and more than 600 mutations have been
identified. Molecular defects in the MEN1 gene have been reported in details [51] and consist
of insertions/deletions with frameshift (40%), non-sense (>20%) and missense (<20%) muta‐
tions, scattered throughout the entire coding region and splice sites of the gene. Large deletions
(1%) may occur and escape direct sequencing, requiring additional molecular techniques such
as Multiple Ligase Probe Amplification (MLPA) for their identification. Most mutations are
supposed to lead to a truncated protein (>70%). Although no clear genotype-phenotype
association has been established, aberrant familial expression of MEN1-related tumours and
reports of severe phenotypes associated with mutations that completely abolish menin
function suggest that this aspect may currently be underestimated [52]. However, in an
increasing proportion of cases, especially in the presence of a sporadic association of MEN1–
related tumours, no MEN1 gene mutations are found (up to 10-30%). In particular, the
relatively common association between PA and primary hyperparathyroidism has been
ascribed to MEN1 in <10% of the cases [53]. MEN1 is a tumour suppressor gene encoding a
610 amino-acid protein, menin, with somatic inactivation of the wild-type allele in MEN1
tumours occurring mostly through LOH. Different MEN1 mouse models have been generated,
including conditional tissue-specific models, which have largely confirming the role of MEN1
inactivation in endocrine tumorigenesis [51]. Recently, pituitary tumour targeting in a MEN1+/-
mice model through in situ injection of the MEN1 gene in adenoviral vectors has proven to
restore menin expression and significantly reduce cell proliferation [54]. Menin is an ubiqui‐
tous nuclear protein, which has been involved in a complex network of protein-protein
interactions and implicated in the regulation of gene transcription, DNA repair and cell
division. Menin suppresses PRL transcription and participates in cell cycle control through the
induction of the cyclin-dependent kinases inhibitor (CKI) genes encoding p27Kip1 and p18Ink4c.
It also interacts with nuclear receptors involved in the control of pituitary function and/or
proliferation such as ERα and PPARγ and with Smad proteins, involved in TGFβ signalling.
A role for menin as a general co-regulator of transcription involved in epigenetic changes on
histone proteins has emerged during the last decade (see “epigenetics”) [55]. Alterations in the
MEN1 gene play a limited role in sporadic pituitary tumorigenesis, and <3% of patients
presenting with apparently sporadic PA have germline MEN1 mutations. However, contrast‐
ing with the expression of menin in all normal pituitary cell types, variable degrees of
underexpression have been reported in all human PA histotypes, with complete loss occurring
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in a PRL-secreting carcinoma [56]. Although LOH in 11q13 may account for reduced menin
expression in a subset of PA, post-transcriptional and post-translational mechanisms are also
likely.
4.1.2. Carney Complex (CNC)
The "complex of myxomas, spotty skin pigmentation, and endocrine overactivity” is a rare and
heterogeneous condition, characterized by the association of endocrine overactivity and
tumors - Primary Pigmented Nodular Adrenocortical Disease (PPNAD), acromegaly, thyroid
and gonadal tumors – with cardiac myxomas, schwannomas and skin pigmented lesions [57].
Primary pituitary presentation is rare and pituitary abnormalities are mainly represented by
an hyperplasia of GH/PRL-secreting cells, which frequently translates into mild hyperprolac‐
tinemia and/or subclinical alterations of GH/IGF1 secretion. Early onset GH/IGF1 hypersecre‐
tion may induce gigantism, but acromegaly and somatotrophinomas develop in a minority of
patients (15%). Up to 70% of CNC patients present in a familial setting, with an autosomal
dominant transmission. Germline heterozygote mutations in the regulatory subunit type 1A of
cAMP-dependent protein kinase (PKRAR1A) gene in 17q22-24 can be identified in ~60% of the
cases, especially in familial forms (80%), with recent evidence for some genotype-phenotype
correlation [58]. Most PKRAR1A mutations are distributed through the coding sequence, 20%
are intronic and affect splicing and two short deletions have been identified as hot spots
[57,58]. LOH at the corresponding locus may be observed in CNC-related PA and conditional
pituitary heterozygous knockout of the PKRAR1A gene is associated with an increased
prevalence of PA arising from the Pit-1 dependent lineage [59], supporting a tumour suppres‐
sor function for PKRAR1A. CNC tumours show increased protein kinase A (PKA) activity and
abnormal activation of the cAMP pathway. A second locus for Carney complex (CNC2) has
been mapped in 2p16 by linkage analysis in CNC kindreds and confirmed by FISH analysis.
Because most alterations were amplifications, undisclosed oncogenes may be involved [57,58].
A missense mutation in the MYH8 gene, encoding the myosin heavy polypeptide 8, has been
exceptionally reported in a CNC variant co-segregating with the trismus-pseudocamptodac‐
tyly syndrome [60]. An increased prevalence of point mutations in the phosphodiesterase
PDE11A gene has also been reported in CNC patients affected by PKRAR1A mutations [61].
However, these variants were associated with an increased prevalence of adrenal and testicular
tumours but did not impact the prevalence of PA.
4.1.3. McCune Albright Syndrome (MAS)
MAS is a rare sporadic disease due to post-zygotic activating mutations in the α subunit of the
stimulatory G protein (GNAS1) gene on 20q13 leading to mosaicism. It is typically characterized
by the clinical triad of café-au-lait skin spots, polyostotic fibrous dysplasia and autonomous
endocrine overactivity syndromes, including peripheral precocious puberty, hyperthyroidism
and GH/IGF-1 and/or PRL hypersecretion [62]. Due to mosaicism, GNAS1 sequencing on
leukocyte DNA is disappointing, since less than 50% can be detected even in the presence of
a typical MAS triad [63]. Pituitary abnormalities are similar to those observed in CNC patients,
with a typical hyperplasia of GH/PRL-secreting cells and somatotrophinomas developing in
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a minority of patients. This can be explained by constitutive activation of the cAMP pathway
as a common molecular hallmark of MAS-and CNC-related cellular abnormalities. In MAS
patients, increased cAMP signalling only occurs in cells affected by activating mutations of
GNAS1, which typically affect the Arginine 201 residue [63].
4.1.4. MEN-4 and other CDKI-related disorders
Inactivating mutations in the CDKN1B gene encoding p27Kip1 have been involved in atypical
multiple endocrine neoplasia syndromes called MENX in the rat and MEN4 in humans,
respectively, where a familial association of acromegaly, hyperparathyroidism, testicular
cancer and angiomyolipomas was reported [64]. In this kindred, both the proband and his
father had acromegaly and a germline heterozygous W76X truncating mutation was found.
Subsequently, additional CDKN1B mutations were reported in MEN1-like patients by
different groups, with hyperparathyroidism appearing as a constant feature and the presence
of additional PA phenotypes being confirmed in some cases (one ACTH-secreting and one
micro-NFPA) [65]. Associated tumours in these patients included gastro-entero-pancreatic
endocrine tumours, carcinoids and papillary thyroid cancer. In most cases, functional studies
in vitro have revealed decreased protein expression, cellular mislocalization in the cytoplasm,
or a defective interaction with protein partners [65]. Search for mutations in CDKN1B and
genes encoding additional CKIs has also been performed in 196 patients with MEN1-like
syndromes. In addition to common benign polymorphisms, mutations in the CDKN1B/
p27Kip1 gene were the most frequently encountered (1.5%), followed by genes encoding
p15Ink4b (1.0%), p18 Ink4c (0.5%) and p21WAF1 (0.5%) [66]. However, PA were associated only with
mutations in the CDKN1B/p27Kip1 and CDKN1A/p21Cip1 genes [66]. Of note, the association
between primary hyperparathyroidism and PA does not appear to be explained by CDKN1B/
p27Kip1mutations [67]. Overall, human CDKI-related conditions are very rare but appear to be
inherited in a dominant manner.
4.1.5. The pituitary adenoma-paraganglioma/pheochromocytoma association: A new syndrome?
Succinate dehydrogenase (SDH) is a mitochondrial enzyme composed of four functionally
different subunits A,B,C,D. Mutations in genes encoding the SDH B,C and D subunits
predispose to pheochromocytomas/ paragangliomas and additional tumours, including
thyroid cancer. Recently, a germline mutation in the SDHD gene leading to a truncated protein
was reported in an acromegalic patient affected by a pheochromocytoma occurring in a familial
context. LOH at the corresponding locus in 11q23 was found in the pituitary GH-secreting
macroadenoma, suggesting a role for SDHD loss in pituitary tumorigenesis [68]. Because the
association between PA and pheochromocytomas/paragangliomas has been reported in the
literature, further search for inactivating mutations in SDH genes is warranted.
4.1.6. Familial Isolated Pituitary Adenomas (FIPA) and the Aryl hydrocarbon receptor Interacting
Protein (AIP) gene
Familial Isolated Pituitary Adenomas (FIPA) are defined by the familial presentation of PA in
the absence of syndromic features. In 2006, 64 European FIPA kindreds were reported,
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including patients affected by prolactinomas (55%), somatotrophinomas (~30%), non-secreting
PA (~15%) and corticotrophinomas (<5%) [69]. The prevalence of FIPA among PA was
estimated about 2-3% and kindreds were almost equally divided into homogeneous and
heterogeneous, as defined by the familial association of PA with a single or multiple pheno‐
types, respectively. Familial homogeneous somatotrophinomas, previously reported as
“Isolated Familial Somatotrophinomas”, accounted for ~20% of the whole series. In the same
year, the Aryl hydrocarbon receptor Interacting Protein (AIP) gene was identified as a predispo‐
sition gene in two large Finnish pedigrees with GH- and/or PRL-secreting adenomas [70]. The
AIP gene was located in 11q13.3 and its causative role in FIPA was soon supported by the
identification of germline AIP mutations in 11/73 FIPA kindreds (15%), including 50% of those
presenting with homogeneous somatotrophinomas and ~10% of heterogenous kindreds [71].
Since this date, AIP-related FIPA have been further identified worldwide [48]. These findings
and the expanding knowledge about the implications of germline AIP mutations and the
potential role of AIP in the pathogenesis of PA have been recently reviewed [48,72] and will
be summarized and updated. Because AIP was originally reported as a “Pituitary Adenoma
Predisposition” (PAP) gene with a low penetrance, and on the basis of accumulating evidence
for an incomplete penetrance of PA in AIPmut-FIPA kindreds, screening for AIP mutations in
patients with an apparently sporadic presentation of the disease was then performed by several
groups. Although AIP mutations were very rarely observed in unselected patients, they could
be identified in 12% of patients presenting with pituitary macroadenomas before the age of 30
[73] and up to 23% of pediatric PA patients [74]. The highest prevalence was found in patients
presenting with gigantism and/or early onset GH/PRL-secreting PA. The phenotype of
AIPmut PA has now been well characterised. Most AIPmut PA are somatotrophinomas (up to
80%), followed by prolactinomas (13.5%) and any other phenotype, with a male predominance
and a frequent early onset of the disease [75]. Compared to their non-AIPmut counterpart, AIPmut
somatotrophinomas are more aggressive and resistant to SSA [74]. AIPmut prolactinomas are
also frequently aggressive and resistant to DA. From a molecular point of view, more than 50
AIP mutations have been identified so far and distributed through the entire coding sequence.
Most are truncating (60-70%) - including the Finnish AIPQ14X founding mutation –, more than
20% are missense and a few hotspots have been reported. Large deletions (10%) and excep‐
tional promoter mutations may also be encountered, in addition to changes of uncertain
biological significance (polymorphisms and non-splicing intron variants). The molecular
pathways involved in AIP-related pathogenesis have not been elucidated yet, but an AIP+/-
mice model has been developed [76]. Interestingly, the wild type strain of mice used for the
generation of the AIP+/- model spontaneously develops prolactinomas, and heterozygous AIP
+/- ablation lead to a full penetrance of PA, with a shift toward a GH-secreting phenotype and
an earlier onset of the disease. While further supporting the tumour suppressing function of
AIP in somatotrophs, these findings highlight the importance of the genetic background and
the contribution of genetic modifiers in the development of AIPmut PA, which have also been
recognized in humans [77]. Pituitary tissue surrounding AIPmut PA has been rarely described,
but hyperplasia was recently reported [78]. The AIP gene encodes a 330 amino-acids cytoplas‐
mic protein (AIP/XAP2/ARA9), which is abundantly expressed by normal somatotrophs and
to a lesser extent by lactotrophs. It is frequently down-regulated in AIPmut PA, due to somatic
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AIP hemizygosity, but also in invasive sporadic somatotrophinomas and in prolactinomas,
whereas it appears to be upregulated in a subset of NFPA [reviewed in 48]. Loss of AIP
expression has been recently proposed as a marker of aggressiveness in sporadic somatotro‐
phinomas [79]. Accordingly GH3 cell proliferation was increased by AIP gene silencing or
inactivation and decreased by overexpression of wild-type AIP, respectively [reviewed in
48,72]. The AIP protein presents a N-terminal immunophilin-like domain (FKBP-52), but its
functional properties appear to be mediated essentially through three tetratricopeptide repeats
(TPR) and a C-terminal α-helix, which are involved in multiple protein-protein interactions.
Identified partners of AIP include: 1) the Aryl Hydrocarbon Receptor (AHR or “dioxin
receptor”), a transcription factor involved in cell response to polycyclic aromatic hydrocarbons
but also in developmental processes and the regulation of cell cycle and differentiation, which
is stabilized in the cytoplasm in a multimeric AIP/AHR/Hsp90 complex; 2) the phosphodies‐
terases PDE4A5 and PDE2A, both implicated in cAMP signalling ; 3) the anti-apoptotic factor
survivin and RET, which prevents the stability of the AIP/survivin complex; 4) members of
the steroid receptor superfamily (eg. PPARα, ERα); 5) viral proteins [48,72]. Most AIP
mutations reported so far may theoretically disrupt one or more functional interactions of AIP
and defective interactions with PDE4A5 have been proven in vitro [72]. An emerging field of
research is the potential role of AIP as a mediator of SSA in the treatment of somatotrophino‐
mas, which would explain the frequent pharmacological resistance of AIPmut tumours. Indeed,
AIP immunostaining was recently reported to be higher in somatotrophinomas treated with
SSA pre-operatively than in untreated tumours [80] and proposed as a predictive factor for
the post-operative response to SSA in these tumours [81] Accordingly, octreotide treatment
was found to increase AIP expression in GH3 cells [80].
4.2. Somatic events in pituitary tumours
Somatic events in pituitary tumours include genetic and epigenetic changes. Intragenic
mutations are less frequently encountered than in other solid tumours. Indeed, oncogene
activation is mainly triggered by the overexpression of genes involved in extracellular
signalling and cell cycle progression, with a few gain-of-function mutations and occasional
rearrangements being reported. Inactivation of tumour suppressor genes is very common and
occurs through epigenetic changes more frequently than through loss-of-function mutations
and/or allelic deletions. MicroRNAs (miRs) have also recently emerged as important regulators
of gene/protein expression in pituitary tumours.
4.2.1. Chromosome and DNA alterations in PA
Several chromosome abnormalities have been reported in PA, although on limited series of
tumours, and include aneuploidy and evidence for intrachromosomal gain or loss of DNA.
For example, trisomies involving chromosomes 5, 8 and 12 appear to be very frequent in
prolactinomas [82], whereas trisomies involving chromosomes 7, 9 and 20 were reported in
NFPA [83]. Conversely, monosomy of chromosome 11 was observed in an aggressive MEN1-
related prolactinoma [84] and LOH with single or multiple allelic deletions at different loci
have been reported, which also appear to be more frequent in invasive PA. For instance, the
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frequency of LOH in 11q13, 13q12-14 and/or 10q26 was found to increase from <10% in low
grade to nearly 75% in high grade PA, according to a modified Hardy’s classification [85]. As
compared to other solid tumours, classical somatic oncogenic mutations are relatively rare in
PA [reviewed in 13,47]. The most frequent oncogenic mutation is represented by activating
missense mutations in the GNAS1 gene, the so-called Gsp oncogene, which has been reported
in up to 40% of somatotrophinomas and occasionally in other phenotypes (<10% NFPA, <5%
corticotrophinomas) [86]. A single B-Raf mutation (V600E) was reported in a NFPA sample
[87]. Other activating mutations have been reported in aggressive tumours, such as activating
H-Ras point mutations in pituitary carcinomas, PKCα in invasive PA and more recently
PIK3CA in pituitary carcinomas and invasive secreting PA [88]. A pituitary specific truncated
form of the FGFR4 (ptFGFR4) endowed with constitutive phosphorylation was also reported
in prolactinomas, and a truncated activin receptor (Alk4), devoided of growth suppressing
activity, has been observed in NFPA [19]. More frequently, overexpression of oncogenic
proteins has been reported in the absence of mutations and ascrìbed to gene amplification or
transcriptional upregulation. These include overexpression of growth factors and cytokines
(eg. TGFα,VEGF) and their receptors (eg. EGFR), proteins involved in the control of cell cycle
and proliferation (eg. cyclins, HMGAs, PTTG, c-myc), cell survival (eg.Bcl2, survivin, BAG1),
intracellular signalling (eg. GNAS1, PIK3CA, Akt) and tumour invasion (eg. MMPs). Somatic
inactivating mutations in TSGs are even less common. Although p53 frequently accumulates
in aggressive PA and especially in pituitary carcinomas, rare mutations have been reported in
carcinomas only [89]. Homozygous deletions in the protein-binding pocket of pRB have been
reported in a minority of PA showing a complete loss of pRb expression [90]. However,
downregulation of TSGs occurs very frequently in PA, due to LOH, epigenetic silencing or
microRNAs dysregulation. Pituitary TSGs have been recognized among proteins involved in
cell cycle control (eg. CKIs, pRb, Zac1), extracellular signalling (eg. TGFβ, BMP4, FGFR2), DNA
repair (eg. p53, GADD45γ) or apoptosis (eg. PTAG, DAPK1), which will be discussed further
on. Current studies on gene expression profiling in PA are giving an important contribution
to the identification of new genes, which expression is dysregulated in PA [10,13,91,92]. It
should be kept in mind, however, that a subset of proteins involved in pituitary tumorigenesis
may be downregulated regardless of gene expression, since increased protein degradation
through the proteasome pathway may in some cases play a prevalent role, as reported for
p27Kip1 or Reprimo [93] and miRs may impact the stability and translation of target mRNAs
(see “microRNAs”).
4.2.2. Epigenetics in PA
Epigenetic changes are mainly characterized by DNA methylation and histone modifications,
leading to chromatin remodelling and regulation of gene expression through a modulation of
DNA accessibility to TFs. Epigenetic changes may coexist with genetic events (eg. inactivating
mutations, LOH). Methylation of cytosine residues in CpG islands of gene promoters is
associated with gene silencing and is inheritable through successive divisions, with de novo
methylation being carried out by the DNA methyltransferase DNMT3, whereas histone
modifications, such as methylation, acetylation, or phosphorylation, are reversible upon
specific enzymatic modifications and their effect on gene transcription can be predicted
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through a “histone code” [94]. For instance, acetylation and trimethylation on specific Lysine
residues (K) on histone 3 (H3K9Ac and H3K4me3, respectively) are associated with an open
chromatin configuration and active gene transcription, whereas other modifications on
histones 3 and 4 (eg. H3K9me3, H3K27me3, H4K12Ac) are associated with a closed chromatin
configuration and gene silencing. Aberrant gene expression due to epigenetic changes can be
involved at all stages of tumourigenesis and is very frequently encountered in PA [95]. An
early event in pituitary tumorigenesis is silencing of the CDKN2A/p16INK4a gene by promoter
methylation, which has been reported in all PA histotypes, though it may be less frequent in
somatotrophinomas. Down-regulation of additional TSGs may be at least partially explained
by gene promoter methylation, including other cell cycle regulators (eg. p15INK4b, pRB, p14ARF,
GADD45γ, neuronatin/NTTA, MEG3), developmental and growth factor signalling molecules
(eg. FGFR2, WIF1, RASSF1A), pro-apoptotic genes (eg. PTAG, DAP kinase, Zac1), genes
involved in cell adhesion (eg. E-cadherin, H-cadherin) and TFs (eg. Ikaros 6) [13,47,95]. Of note,
a minority of these genes are normally imprinted (eg. MEG3, Zac1, NNTA). In contrast,
promoter hypomethylation can induce overexpression of pituitary oncogenes. For instance,
loss of imprinting of the GNAS1 gene may be responsible for an overexpression of the wild-
type gene, mimicking the effects of the Gsp oncogene. Abnormal expression of MAGE-A3, an
X-chromosome linked gene silenced by thorough promoter methylation in normal pituitary
cells, has been explained by promoter hypomethylation in PA [96]. Further characterization
of DNA methylome by specific array techniques appears as a promising tool for the identifi‐
cation of new genes modified by abnormal methylation patterns [97]. Histone modifications
may contribute either to transcriptional repression, as reported for FGFR2 [96] and BMP4 [98],
or to increased gene expression, as reported for the estrogen-induced MAGE-3A expression
[96] or for DNMT3 [95]. An interesting function of menin as a co-regulator of transcription
though histone changes has also been proposed to explain several alterations in gene expres‐
sion observed in MEN1-related tumours [55]. Menin is able to tether histone deacetylase
activity to genes, thereby repressing gene expression, as reported for JunD- or NF-kB-
dependent transcription. On the other hand, as a part of Mixed Lineage Leukemia (MLL)
protein-containing complexes which specifically triggers H3K4me3 trimethylation, menin has
been involved in the activation of several genes, including homeobox genes (Hox),
CDKN1B/p27Kip1, CDKN2C/p18Ink4 and nuclear hormone receptor sensitive genes. These
functions of menin and their final effects on cell proliferation depend on the cellular context
and may explain why menin acts as a TSG in endocrine cells and a co-oncogenic protein in
leukemias [99].
4.2.3. The emerging role of microRNAs and other non-coding RNAs
MicroRNAs (miRs) are small non-coding RNA molecules (18-25 nucleotides) involved in the
post-transcriptional regulation of mRNAs stability. More than 600 miRs have been reported
in the human genome and up to 30% of genes are believed to be regulated by miRs. Briefly,
miRs derive from the intracellular processing of precursors called pri- and pre-miRNAs, and
mature miRs bind to the 3’ untranslated sequence of mRNA target molecules, leading to the
formation of miRs duplexes. MiRs duplexes are incorporated into protein containing RNA-
induced silencing complexes (RISC) and, according to their degree of complementarity with
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miRs, target mRNAs can be cleaved (perfect complementarity) or undergo partial degradation
and translational inhibition (imperfect complementarity, which is the most common figure).
MiRs have been involved in the control of pituitary development [100] and function [101].
Alterations in miRs expression profile, including loss or gain of expression, have been
increasingly involved in pituitary tumorigenesis. Since the first report on miR15a and miR16-1
downregulation in GH- and PRL-secreting macroadenomas [102], more than 100 dysregulated
miRs have been identified in PA, with phenotype-specific expression profiles being reported
in GH- and/or PRL-secreting, ACTH-secreting or NFPA [103-112]. Although in most cases their
biological significance is not fully understood, several miRs have been involved in the control
of pituitary cell cell proliferation, differentiation, apoptosis, cell adhesion and metabolism, and
a subset has been linked to a more aggressive behavior or even to malignant transformation
[103, 104, 110]. Target mRNAs are also being increasingly recognized. For instance, Bcl2 mRNA
is a target for miR-16-1 and the expression of Bcl2 can be upregulated as a consequence of
miR-16-1 down-regulation, contributing to promote cell survival. In somatotrophinomas, loss
of miR-126 contributes to cell proliferation through an upregulation of the PI3K regulatory
subunit β (which amplificates PI3K signalling) [104], whereas upregulation of miR-107 has
been recently involved in AIP silencing [105]. Overexpression of PTTG and HMGAs in PA
may also be partially explained by specific miRs dysregulation [104, 106,107]. Another
interesting aspect is the potential role of LOH in the dysregulation of miRs expression, as
reported for miR-15a and miR-16-1 which may be underexpressed as a consequence of LOH
in 13q14. There is also recent evidence that the miRs profile in PA may be influenced by their
pre-operative pharmacological treatment, as reported in somatotrophinomas treated by
lanreotide [106] and in prolactinomas treated by bromocriptine [108]. A non exhaustive list of
miRs involved in pituitary tumorigenesis is shown in Table 2. Other non-coding RNAs may
also be implicated. The Maternally Expressed Gene 3 (MEG3), a large non-coding RNA molecule
expressed by normal pituitary cells and selectively lost in NFPA, suppresses cell proliferation
through p53-mediated/p21 independent and pRB-mediated pathways [113]. MEG3 is part of
the imprinted DLK1/MEG locus, where maternally expressed genes (eg MEG3) are non-coding
RNAs and paternally expressed genes (eg DLK1) encode proteins. Interestingly, silencing of
the DLK1/MEG locus in NFPA is responsible for the underexpression of additional non-coding
RNAs, including several miRs [114].
MicroRNA Cromosome
map (h)
Molecular defect Histotype Function Ref.
miR-128a 2q21.3 Overexpression NFPA Target gene: Wee1 (↓) 109
Down-regulation All PA
GH
Target gene: BMI1* (↑) 103
111
miR-26a/b 3p21 (a)
2q35 (b)
Overexpression NFPA (miR-26a)
GH (miR-26a/b)
Potential target genes:
Hox-A5, PLAG1
Target gene (miR26b):
PTEN (↓)
103
111
Down-regulation GH/PRL/NFPA
(miR 26a)
Target genes: HMGA1,
HMGA2 (↑)
112
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MicroRNA Cromosome
map (h)
Molecular defect Histotype Function Ref.
miR-191 3p21 Overexpression All PA Cell proliferation 103
miR-145 5q32 Down-regulation GH Target genes: c-myc, k-
ras, c-fos,
cyclin D2, MAPK (↑)
106
miR-30a/b/c/d 6q13 (c);
8q24.2 (b)
Overexpression ACTH - 103
miR-320 8p21.3 Overexpression GH - 107
miR-24-1 9q22.1 Down-regulation All PA Predicted target genes:
VEGFR1 and several
oncogenes
103
Let7-a 9q22.32 Down-regulation All PA Target genes: HMGA1,
HMGA2 (↑)
Potential target genes:
Ras
103,
104, 112
miR-126 9q34.3 Down-regulation GH Amplification of PI3K
signalling;
PTTG (↑)
106
miR-107 10q23 Overexpression GH/ NFPA Target gene: AIP (↓) 105, 111
miR-326 11q13.4 Down-regulation GH, some PRL
NFPA
Target genes: HMGA1,
HMGA2, E2F (↑)
107
miR-141 12p13 Down-regulation ACTH Tumor growth and
tumor local invasion
103
miR-16-1 13q14 Down-regulation All PA Target genes: HMGA1,
HMGA2, Bcl2 (↑)
102-
104, 112
miR-15a 13q14 Down-regulation All PA, in particular
GH/PRL
Target genes: HMGA1,
HMGA2 (↑)
102,
103, 112
miR-20a 13q31.3 Overexpression NFPA Target gene: Wee1(↓) 109
miR-493 14q32.2 Overexpression ACTH (carcinoma) Target genes: LGALS-3
and RUNX2 (↓)
110
miR-381 14q32.31 Down-regulation GH Target gene:
PTTG (↑)
106
miR-140 16q22.1 Overexpression NFPA
(macroadenomas)
Tumor growth 103
miR-212 17p13.3 Overexpression All PA Target gene: DEDD (↓),
↑ apoptosis
103
miR-132 17p13.3 Down-regulation All PA - 103
miR-152 17q21 Overexpression All PA Cell proliferation 103
miR-122 18q21.31 Overexpression ACTH (carcinoma) - 110
miR-23a 19p13.13 Overexpression GH/PRL - 103
miR-24-2 19p13.13 Overexpression GH/PRL See miR-24-1 103
Down-regulation ACTH/ NFPA See miR-24-1 103
miR-155 21q21.3 Overexpression GH/PRL/NFPA Target gene: 109
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MicroRNA Cromosome
map (h)
Molecular defect Histotype Function Ref.
Wee1 (↓)
miR-098 Xp11.2 Down-regulation All PA Predicted target genes
involved in cell
progression,
cytoskeleton and vesicle
organization
103
*a transcriptional repressor of PTEN
Table 2. Differential expression of microRNAs in pituitary tumours
5. Alterations in neuropeptide signalling in pituitary tumours
Hypothalamic peptides play an essential role in normal pituitary cells and their biological effects
are mediated by G-protein coupled receptors (GPCRs) [19]. In addition to their dynamic control
on pituitary hormone secretion and release, they may exert trophic effects on target cells - such
as GHRH and CRH on somatotrophs and corticotrophs, respectively – or limit their prolifera‐
tion – such as dopamine in lactotrophs. The expression of neuropeptide receptors is generally
conserved in pituitary tumours and represents the molecular basis for their pharmacological
treatment with DA and SSA [2]. However, abnormal expression of these receptors may be
involved in paradoxical responses or in pharmacological resistance. Neuropeptides may also
be produced by the pituitary gland or ectopically by neuroendocrine tumours, and their ectopic
secretion may lead to pituitary hyperplasia and/or adenoma. Finally, abnormal intracellular
signalling may occur in PA, contribute to pituitary tumorigenesis and potentially influence the
response to pharmacological treatment. An extensive review of such processes would be beyond
the scope of this work, so we will focus on the most relevant and recent findings in this field.
5.1. Abnormalities in the cAMP-PKA pathway
The cAMP/PKA pathway is essential in pituitary cells, especially in somatotrophs and in
corticotrophs. Briefly, the α-subunit of the stimulatory G protein (Gsα), encoded by the GNAS1
gene, is required for the activation of adenyl cyclase and the generation of cAMP in somato‐
troph and corticotroph cells in response to GHRH and CRH, respectively, whereas the α-
subunit of the inhibitory G protein (Gi) inhibits adenylate cyclase activity and decreases cAMP
signalling in response to dopamine, somatostatin and their pharmacological analogues. As
already reported, somatic activating mutations in the GNAS1 gene – the Gsp oncogene – are
frequent in somatotrophinomas whereas post-zygotic mutations are associated with the MAS
syndrome. The GNAS1 locus is under a complex imprinting control and GNAS1/Gsp muta‐
tions are exclusively found on the maternal allele. Gsp+ somatotrophinomas were first charac‐
terized by high adenyl cyclase activity and high intracellular cAMP concentration. However,
conflicting results concerning the phenotype of Gsp+ somatotrophinomas arised from large
studies comparing Gsp+ and Gsp- tumours [86]. In particular, no significant differences were
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found concerning their hormone secretion profile and tumour aggressiveness. This could be
partially explained by the development of molecular mechanisms able to counteract a sus‐
tained increase in cAMP concentration, such as an increased phosphodiesterase (PDE) activity,
in particular PDE4, in Gsp+ tumours. In addition, the Gs protein is instable and barely detecta‐
ble in Gsp+ tumours, whereas an overexpression of the wild-type Gsα protein can be observed
in Gsp- tumours [86,115]. Accepting the concept that Gsp mutations represent an early pathoge‐
netic event, long-standing Gsp+ tumours may also have accumulated additional molecular
abnormalities able to modify their early phenotype. However, most studies indicate that Gsp+
somatotrophinomas are significantly smaller than their Gsp- counterpart and show a better
response to SSA. This could be explained in vitro by a greater effect of cAMP decrease in the
presence of high basal cAMP concentrations. The presence of a cAMP-responsive element (CRE)
in the SSTR2 promoter also suggested that constitutive activation of the cAMP/PKA pathway
might result in an increased sentivity to SSA, but no difference in SSTR2 expression has been
found between Gsp+ and Gsp- adenomas. However, considering the proliferative effects of the
cAMP/PKA pathway in somatotrophs, the smaller volume of Gsp+ tumours is intringuing and
suggests that cAMP signalling is also linked to somatotroph differentiation. A few additional
mutations in G proteins have been reported in PA, among which rare mutations involved in
IP3/calcium signalling [86]. Additional abnormalities in cAMP signalling are represented by
dysregulated protein kinase A (PKA) activity. In its inactive form, PKA is composed of two
regulatory and two catalytic subunits. These latter are released when the intracellular cAMP
concentration increases and bind the regulatory subunits. The inactivating mutations in the
PRKAR1A gene encoding the type 1α regulatory subunit of PKA reported in patients affected
by CNC is associated with increased cAMP signalling, probably through an altered equilibri‐
um between regulatory and catalytic PKA subunits [57]. No somatic PRKAR1A mutations have
been observed in PA. However, a marked reduction in PRKAR1A protein expression was
reported in PA of different histotypes, due to an increase in proteasome-mediated protein
degradation [116]. This was found to result in an imbalance between the R1 and R2 isoforms of
the PKA regulatory subunit, which in turn was associated with an increased cell proliferation
in GH3 cells and increased Cyclin D1 expression in somatotroph PA. Following the discovery
of missense and inactivating mutations in adrenal and testicular tumours, variants in the
PDE11A gene have been reported in 17% of acromegalic patients [117]. Due their high frequen‐
cy in the control population and the absence of phenotypic changes in the corresponding
tumours, these variants were unlikely to be pathogenic. Accordingly, PDE11 variants in CNC
patients were not found to increase the prevalence of PA [61]. However, a single truncating
mutation was observed and LOH at the corresponding locus was found in an additional tumour,
with decreased PDE11A immunoreactivity in both cases, suggesting that genetic alterations in
PDE11A may occasionally contribute to pituitary tumorigenesis [117].
5.2. Neuropeptides, neuropeptide receptors and their implications in pituitary tumour
pathogenesis and treatment
Abnormal hypothalamic neuropeptide signalling has long been involved in the pathogene‐
sis of PA. GHRH stimulates somatotroph proliferation and causes somatotroph hyperpla‐
sia in mice, with PA developing in old transgenic GHRH animals. Hypothalamic acromegaly
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has been exceptionally reported in patients with gangliocytomas [118] and ectopic secre‐
tion of GHRH by neuroendocrine tumours has been well characterized. In a retrospective
analysis of 21 patients with ectopic acromegaly [119],  most patients showed radiological
evidence of pituitary enlargement, but 5 had normal pituitary imaging and 6 had suspect‐
ed  PA,  respectively.  Out  of  the  four  cases  who  underwent  pituitary  surgery,  all  had
somatotroph  hyperplasia  and  2  had  concomitant  GH/PRL-secreting  PA.  Noteworthy,  a
MEN1 context was identified in 8/11 cases. Ectopic secretion of CRH by neuroendocrine
tumours may cause ACTH-dependent hypercortisolism, but this is an exceptional condi‐
tion  and  ectopic  secretion  of  ACTH  and  other  POMC-derived  peptides  is  by  far  most
frequent.  TRH  stimulates  thyrotrophs  and  lactotrophs,  mainly  through  the  IP3/calcium
pathway, and patients with long-standing, severe, primary hypothyroidism may develop
pituitary thyrotroph and lactotroph hyperplasia due to an altered feedback on TRH/TSH
secretion. Similar mechanisms are involved in gonadotroph hyperplasia secondary to long-
standing  hypogonadism  (of  note,  pituitary  hyperplasia  is  not  a  feature  of  menopause).
However, true “feed-back” PA are rare and are likely to require additional somatic events.
Abnormal/ectopic,  expression  of  neuropeptide  receptors  may  also  occur  in  PA  and  ac‐
count for some “paradoxical” responses observed in vivo or in vitro (eg. GH increase after
TRH or GnRH stimulation in acromegalic patients) [120]. Loss of hormonal inhibition might
also be involved in pituitary cell dysregulation. Dopamine maintains a tonic inhibition on
PRL secretion and cell proliferation in lactotrophs through the dopaminergic receptor D2R.
In prolactinomas, neovascularization by-passing the hypothalamus has been proposed to
allow tumor cells  to  escape dopamine inhibition.  D2R-deficient  mice develop lactotroph
hyperplasia and late-onset adenomas, especially in females [6]. However, no mutations in
the D2R gene have been identified in human prolactinomas and most of them respond to
DA in terms of prolactin normalization and tumour shrinkage. Reduced D2R expression, in
particular of its short isoform, is frequently observed in resistant prolactinomas [121]. An
essential  role  for  the  cytoskeleton-associated  protein  filamin  A  in  D2R  expression  and
signalling has been recently shown in MMQ cells and reduced filamin-A expression has
been  associated  with  low  D2R  expression  and  pharmacological  resistance  in  human
prolactinomas  [122].  Similarly,  hypothalamic  somatostatin  inhibits  GH  secretion  and
somatostatin receptors (SSTRs) are expressed on somatotrophinomas. Among the five SSTRs
subtypes, SSTR2 and SSTR5 mediate most of the therapeutic effects of SSA in these tumours.
Although there is no evidence that loss of somatostatin inhibition plays a role in pituitary
tumorigenesis, abnormal somatostatin signalling may impact the outcome of pharmacolog‐
ical treatment [123]. Resistance to SSA in somatotrophinomas has been associated with low
SSTR2 expression and a few genetic abnormalities in SSTR5, including an inactivating SSTR5
missense mutation in the third intracellular loop and LOH at the SSTR5 gene locus [117].
The  truncated isoform of  SSTR5,  sst5TDM4,  may also  reduce  the  efficacy  of  SSA [124].
Finally, the pituitary gland produces neuropeptides with paracrine effects on pituitary cells
(eg. galanin, bombesin, VIP, PACAP) [19,125]. Some of these peptides may also play a role
in pituitary tumorigenesis, as suggested by animal models such as transgenic mice overex‐
pressing galanin under the control of the GH promoter, which develop pituitary hyperpla‐
sia and adenomas [126].
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6. Dysregulated cell growth and survival in pituitary tumours
Alterations in cell cycle control and imbalance between cell proliferation and apoptosis are
general mechanisms in tumours. Such alterations may be driven by abnormal extracellular
signalling and/or abnormal intracellular responses to extracellular signals, including constit‐
utive activation of proliferative pathways and/or escape to normal regulatory signals.
6.1. Extracellular signalling in PA
In addition to neuropeptides, pituitary cells depend on extracellular signalling from the
extracellular matrix, a variety of growth factors (GFs) and peripheral hormones secreted by
target glands. Extracellular signalling molecules are involved in a complex network of
paracrine and autocrine pathways, which are tightly regulated in the developing and adult
pituitary [125]. Cell-to-cell signalling regulates pituitary hormone secretion, cell differentia‐
tion, growth, survival and plasticity, as well as angiogenesis. Abnormal signalling may
therefore participate in pituitary tumorigenesis.
6.1.1. Growth factors and cytokines
The pituitary gland is an abundant source of GFs, in particular the FGF, EGF and VEGF
families, and cytokines (the TGFβ family, interleukins and chemokines) [19,125]. Due to the
abundant literature in this field, we will present an overview of the best studied GFs and
related pathways in PA. FGFs play an important role in pituitary development. FGFs include
>20 members and FGF signalling is mediated by 4 FGF receptors (FGFR1-4), with different
isoforms (cell-bound, secreted, truncated) generated by alternative splicing. FGFs and FGFRs
are involved in proliferative and anti-proliferative signals. The heparin-binding secretory
transforming (hst) gene encoding FGF4, was first identified in prolactinomas, with strong FGF4
immunostaining being correlated with tumour invasiveness [127]. A tumour specific N-
terminally truncated FGFR4 (ptdFGFR4), characterized by an exclusive intracellular localiza‐
tion and constitutive phosphorylation, was also identified in PA of different histotypes and
proven to be tumorigenic in vitro and in vivo [128]. FGF2 has been involved in the pathogenesis
of estrogen-induced experimental prolactinomas [129]. In contrast, signalling through the
FGFR2 by FGF7 has anti-proliferative effects and down-regulation of FGFR2 has been reported
in a subset of PA, in particular prolactinomas [130]. The TGFβ superfamily includes several
members (TGFβ1-3, activin/inhibins and BMPs), which may exert either collaborative or
opposing signalling on different pituitary cells and PA histotypes. TGFβ signalling is mediated
by Smad proteins and generally inhibits cell proliferation. All TGFβ isoforms and their receptor
TGFβ-R-II are expressed in PA, and TGFβ inhibits estrogen-induced lactotroph proliferation
and PRL secretion [131]. Activin normally increases the synthesis of FSH while inhibiting that
of PRL, GH and ACTH and exerts anti-proliferative effects on lactotrophs and prolactinoma
cells [132]. Truncated activin receptors (Alk4) have been reported in PA, with a dominant effect
opposing the antiproliferative effects of activin [133]. Inactivation of menin also blocks the anti-
proliferative effects of TGFβ and activin on lactotrophs [132]. In contrast, BMP4 promotes the
proliferation of GH/PRL-secreting cells and the development of prolactinomas, while inhibit‐
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ing the proliferation of corticotrophs [134]. Accordingly, BMP4 is up-regulated in prolactino‐
mas and down-regulated in corticotrophinomas [19]. Interestingly, BMP4 is down-regulated
by DA in prolactinomas [108]. Other cytokines produced by the pituitary gland include
interleukin 1 (IL1) 1 and TNFα, leukemia inhibitory factor (LIF), macrophage migration
inhibitory factor (MIF), interferon γ, interleukins 2 (IL2) and 6 (IL6), which potential role in
PA has not been extensively studied [131]. An increasing attention has been paid to IL6, which
is normally produced by FCS cells but is secreted by tumour cells in PA, where it has been
involved in cell proliferation, angiogenesis and oncogene-induced senescence [131]. Chemo‐
kines have also been increasingly involved in ontogenesis and cancer. The chemokine receptor
CXCR4 is expressed in the normal pituitary and its ligand, the Stromal-cell Derived Factor
SDF1/CXCL12, was found to increase GH/PRL secretion and cell proliferation in GH4C1 cells.
An overexpression of CXCR4 and, to a lower extent, SDF1, has been reported in somatotro‐
phinomas and NFPA [135]. EGF expression has been observed at all stages of pituitary
development and in the adult pituitary, and the EGFR pathway contributes to pituitary
physiology and tumorigenesis [136]. It is involved in the control of corticotroph and gonado‐
troph functions at both hypothalamic and pituitary levels and modulates hormone secretion
and proliferation in GH/PRL-secreting cells. More than 60% of PA, in particular the secreting
histotypes, have been shown to express EGFR by different techniques, whereas ErB2 was found
in ~30% of PA, especially in NFPA [136]. Both have been positively correlated with tumour
invasiveness. The EGFR pathway is of particular importance for corticotroph tumorigenesis.
Overall, 75% of corticotrophinomas express EGFR [136]. The strongest positivity for EGFR and
its phosphorylated form was found in corticotrophinomas and associated with p27 down-
regulation [137]. Recently, nuclear localization of EGFR was observed in human and canine
corticotrophinomas and associated with increased POMC transcription, whereas inhibition of
EGFR tyrosine kinase activity by gefitinib decreased hormone secretion and cell proliferation
in vitro and in vivo [138]. More than 50% of GH- and/or PRL-secreting PA also express EGFR
[136]. However, the role of EGFR signalling in these tumours is less clearcut. EGF enhances
the proliferation of lactotrophs and PRL transcription and TGFα has been involved in estrogen-
related lactotroph proliferation. On the other hand, EGF is able to induce lactotroph differen‐
tiation in GH3 cells, with a decrease in GH secretion, an increase in PRL secretion and an
induction of D2R expression, with conflicting data reported on cell proliferation. Gefitinib was
found to decrease cell proliferation of GH3 cells, with a reduction in PRL and an increase in
GH secretion, respectively [139]. The dual EGFR/HER2 tyrosine kinase inhibitor lapatinib
showed similar or stronger effects on GH3 cells, attenuated the effects of estrogens in estrogen-
induced prolactinomas in vivo and suppressed PRL secretion from human prolactinomas in
vitro [138]. Interestingly, EGFR expression was positively correlated with p27 immunostaining
in somatotrophinomas [137]. The role of EGFR signalling in NFPA has not been extensively
studied yet. NGF is the best characterized neurotrophin in the pituitary and NGF signalling
is mediated by TrkA and p75NTR, a member of the TNF receptor superfamily. All Trk receptors
have been observed in the normal pituitary and in PA [140]. NGF plays a role in lactotroph
differentiation and in the stress-related stimulation of corticotroph function, and escape to
NGF control has been involved in the pathogenesis of prolactinomas. NGF induces lactotroph
differentiation of GH3 cells similarly to EGF, exerts autocrine anti-proliferative actions on
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prolactinoma cells and loss of NGF expression in prolactinomas has been linked to low D2R
expression and pharmacological resistance [141]. The VEGF is a family of angiogenic factors
composed by 6 members, including VEGFA (also known as VEGF), which effects are mediated
by two tyrosine kinase receptors (VEGFR1 and KDR/Flk-1/VEGFR2). VEGF and its receptors
are differentially expressed in normal pituitary cells and in PA [142]. In particular, VEGF and
KDR are markedly upregulated in NFPA. Overexpression of VEGF and KDR mRNAs in PA
was recently associated with extrasellar growth and a shorter recurrence-free survival,
respectively [143].
6.1.2. Steroid hormones
Steroid  hormones  may  play  an  important  role  in  pituitary  tumorigenesis.  The  best
characterized  model  is  represented  by  estrogen-induced  lactotroph  hyperplasia  and
prolactinomas.  Estrogen-induced  lactotroph  hyperplasia  occurs  physiologically  during
pregnancy, but sustained estrogen exposure may lead to prolactinomas in some strains of
rats.  Although  evidence  for  estrogen-induced  prolactinomas  in  humans  is  very  poor,
prolactinoma  growth  and/or  intra-tumoral  hemorrhage  may  occur  during  pregnancy,
especially  in  macroprolactinomas  [144].  Among  PA,  prolactinomas  express  the  higher
concentration  of  ER  [145]  and  estrogens  can  increase  PA  cell  proliferation  in  primary
culture [146]. Importantly, ERα and ERβ play distinct roles and an imbalance between these
two isoforms has been reported in PA. Indeed, nuclear overexpression of ERα has been
linked to tumour aggressiveness in prolactinomas and NFPA, whereas invasive NFPA were
found to express lower ERβ [147]. Ablation of ERβ in mice was also associated with the
development  of  invasive  gonadotrophinomas  in  females  [148].  Estrogens  exert  multiple
effects on pituitary cells, especially on lactotrophs. They enhance the transcription of the
PRL gene, as well as PTTG and genes encoding other growth-promoting proteins, such as
c-myc  and GFs [149]. Based on the comparison of microarray profiles obtained in human
prolactinomas and in estrogen-induced rat prolactinomas, a common set of genes has been
identified, supporting a major role for E2F1, c-myc and Igf1 in their pathogenesis [92]. GFs
have  been  involved  in  an  interplay  between  FCS  and  lactotrophs,  with  the  estrogen-
induced  increase  in  TGF-β3  secretion  by  lactotrophs  being  proposed  to  stimulate  FGF
release by FCS cells, which in turn stimulate latotroph proliferation. Estrogens also increase
the  secretion  of  VEGF  and  FGF2,  thereby  enhancing  angiogenesis.  Indeed,  estrogen-
induced prolactinomas are strongly vascularised, spontaneous hemorrhage may occur, and
high ER concentrations were found in hemorrhagic PA [145]. In contrast, estrogens inhibit
the secretion of the anti-proliferative TGFβ1 and TGFβ2 [150].  Finally, estrogens contrib‐
ute to reduce the inhibitory effects of dopamine on lactotrophs, in part by favouring the
expression  of  the  long  form  of  D2R  [150].  Noteworthy,  estrogens  are  also  involved  in
pituitary plasticity, and a pro-apoptic role of estrogens through membrane ERs and TNF/
TNFR1 has been involved in lactotroph cells  renewal during the estrous cycle [151,152].
Other gonadal steroids may play a role in PA, since receptors for androgens and progester‐
one may also be expressed in PA and associated with the modulation of their prolifera‐
tion by their relative agonists in vitro [145,146]. Lack of steroid feed-back on pituitary cells
can  also  be  involved  in  pituitary  tumorigenesis,  but  as  already  mentioned,  true  “feed-
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back”  gonadotroph  PA  are  very  rare.  The  potentially  aggressive  Nelson’s  syndrome,
defined  by  corticotrophinoma  growth  after  bilateral  surrenalectomy  for  Cushing’s  dis‐
ease, provides indirect evidence that glucocorticoid excess previously contributed to control
cell  proliferation.  However,  different  degrees  of  impaired  glucocorticoid  feedback  are
observed in Cushing's and Nelson’s tumours. A glucocorticoid-receptor (GR) mutation that
diminished glucocorticoid inhibition has been reported in a single Nelson’s tumour,  but
GRs  are  generally  overexpressed  in  corticotrophinomas,  and  at  the  moment  the  best
candidates for glucocorticoid resistance are Bgr1 and HDAC2, which are involved in the
GR-dependent repression of POMC and are deficient in about 50% of corticotroph PA [153].
Bgr1  is  a  tumour suppressor  and loss  of  nuclear  Bgr1  has  been associated with  loss  of
p27Kip1 expression [153].
6.1.3. Adhesion molecules
Adhesion molecules are important to maintain cell-to-cell contact and a normal cell morphol‐
ogy and tissue architecture. Similarly to other epithelial tumours, PA may develop some
degree of epithelial-to-mesenchymal transition, which is associated with loss of cell adherence
and tumour aggressiveness. The N- and C-cadherins are involved in pituitary development
and in the organization of the adult pituitary into a functional network involving FCS cells
[154]. E-cadherin has been largely recognized as a TSG in the pituitary. Reduced E-cadherin
expression was first associated with an aggressive behavior in prolactinomas [155]. Subse‐
quently, downregulation of the E-cadherin gene (CDH1) and decreased E-cadherin expression
has been reported in different PA phenotypes. The reduced expression of E-cadherin was
associated with its redistribution from the cell membrane to the nucleus in invasive tumours
[156]. Similar findings were recently reported in a large series of somatotrophinomas [157]. In
this latter study, pre-operative treatment with SSA was associated with increased E-cadherin
expression, although its nuclear localization correlated negatively with tumour shrinkage
[157]. A positive association between reduced E-cadherin expression, increased nuclear E-
cadherin and tumour aggressiveness has also been reported in corticotrophinomas, with a
gradual decrease from micro- to macro-adenomas and Nelson’s tumours [158]. Neural
adhesion molecules (NCAMs) can be modified by polysialation. Polysialated NCAMs, which
are implicated in cell proliferation and migration, have been involved in pituitary tumour
invasiveness [91,159].
6.2. Abnormalities in cell cycle control
The main positive regulators of the cell cycle are the cyclin dependent kinases (CDKs), which
are activated by specific associations with cyclins (A, B, D, E). The progression through the
different phases of the cell cycle, in particular the G1/S and G2/M transitions, are stimulated by
cyclin/CDK complexes and suppressed by their inhibitors, CKIs. The latter are divided into
the INK4 family (p16Ink4a, p15Ink4b, p18Ink4c), which negatively regulates the G1/S transition
through a direct interaction with the CDK4/6 containing complexes, and the so-called “uni‐
versal” Cip/Kip family (p21Cip1, p27Kip1, p57Kip2), which is involved at various phases of the cell
cycle by interacting with different cyclin/CDK complexes. Down-regulation of cell cycle
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inhibitors (eg CKIs, pRB) and overexpression of molecules involved in cell cycle progression
(eg. cyclins, PTTG and HMGA proteins) are among the best characterised mechanisms of
pituitary tumorigenesis [160]. The pituitary phenotype associated with genetic alterations in
cell cycle regulators has been studied in several mouse models, including double mutants
[160]. Some of the best characterized molecules involved in the dysregulation of cell cycle in
PA are illustrated in Figure 1
Figure 1. Cell cycle dysregulation in pituitary tumours
6.2.1. Abnormalities in cell cycle progression
Increased expression of D-type cyclins is a key event in the exit from the quiescent G0 state
under mitogenic stimulation by GFs. They activate CDK4 and CDK6, which phosphorylate
pRB and therefore indirectly induce the transcription of S-phase genes by releasing TFs of the
E2F family from their interaction with pRB. Transition from late G1 to the S phase is also driven
by Cyclin E/ CDK2 complexes. Overexpression of cyclins D1 and D3 has been reported in PA
of different histotypes [160]. In particular, Cyclin D1 is overexpressed in ~70% of NFPA and
40% of somatotrophinomas, especially in invasive PA, with allelic imbalance suggesting gene
amplification in 25% of the cases [161]. Increased GFs and Wnt/β-catenin signalling is also
likely to contribute to CCDN1/cyclinD1 expression in PA. In contrast, cyclin E overexpression
Hot Topics in Endocrine and Endocrine-Related Diseases52
has been mostly reported in corticotrophinomas, where it has recently been correlated with
the loss of Bgr1 expression [162]. Overexpression of Cyclin E under the control of the POMC
promoter in transgenic mice was shown to promote re-entry in the cell cycle and centrosome
instability [162]. CDK4 is involved in pituitary ontogenesis. Although PA may develop in the
anterior lobe of transgenic mice expressing a CDK4 missense mutation (R24C), which inhibits
its interaction with INK4 proteins, it does not appear to play a major role in human PA. The
tumour suppressor function of pRB in the pituitary has long been recognized in rodents, with
pRB+/- mice developing tumours of the intermediate lobe. In humans, loss of pRB expression
in PA mainly occurs through LOH in 13q14 or promoter methylation, especially in invasive
PA, though homozygous deletions in the protein-binding pocket can be found [90]. Reduced
expression of the INK4 family members of CKIs - p16Ink4a and, to a lesser extent, p15 Ink4b, which
are encoded by adjacent genes in 9p21 - has been frequently reported in PA and methylation
of the CDKN2A/p16 Ink4a gene promoter is considered as a precocious event [160]. Overall,
abnormalities of the cyclinD/pRb/p16 Ink4a pathway have been reported in 93% of NFPA and
56% of somatotrophinomas [163]. The role of p18In4c in pituitary tumorigenesis has been shown
in mouse models. A reduced expression of p18In4c has been observed in a subset of PA, due to
promoter methylation or, less frequently, LOH at the corresponding locus [164]. The CDKN2C/
p18In4c gene is a target of menin and p18In4c collaborates with menin to suppress pituitary
tumorigenesis. Although failure to adequately control cell cycling at G1/S transition is consid‐
ered as a mandatory step in tumorigenesis, loss of adequate control of the G2/M transition
represents an important additional event [165]. In particular, DNA damage can induce G2
arrest as a result of the activation of ATR and ATM kinases, which activate p53-dependent and
-independent intracellular cascades [165]. A reduced expression of Wee1, which induces an
inhibiting phosphorylation of Cdk1 and therefore contributes to prevent G2/M progression,
has been reported in somatotrophinomas and NFPA [109]. An increased expression of Cyclin
A has been reported in PA of different histotypes [160] and similar findings were reported for
Cyclin B1 and B2, especially in prolactinomas [166,167]. Genes induced by p53 upon genotoxic
stress include GADD45, p21 and Reprimo. GADD45γ is strongly down-regulated in most PA
[168] and GADD45β has been identified as a TSG in gonadotrophinomas [169]. Reprimo has
also been recently characterized as a pituitary TSG, especially in gonadotroph and somato‐
troph tumours [93]. Down-regulation of universal CKIs and upregulation of PTTG and
HMGAs may contribute to cell cycle dysregulation at different stages.
6.2.2. The universal Cip/kip CDKI family
Both p27Kip1 and p21Cip1/Waf1 have been involved in pituitary tumorigenesis. The p27Kip1 protein
is normally localized in the nucleus of quiescent cells and undergoes rapid degradation upon
mitogenic stimulation. Phosphorylation of p27Kip1 is involved in its degradation through the
ubiquitin/proteasome pathway. Loss of nuclear p27 Kip1 due to a reduced expression or an
abnormal cytoplasmic localization has a negative prognostic value in a variety of human
neoplasia. CDKN1B/ p27Kip1 is a haploinsufficient gene. In mice, both heterozygous and
homozygous ablation of the CDKN1B gene induce pituitary tumours of the intermediate lobe
and a collaborative effect with cyclin E up-regulation has been reported [162]. As reported
hitherto, germline CDKN1B gene mutations are associated with MEN1-like syndromes (MEN4
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in humans) [64], but this is a very rare condition. Down-regulation of p27Kip1 has been reported
in human PA, especially in corticotrophinomas and in pituitary carcinomas, due to an
increased protein phosphorylation and degradation, with no significant alterations in
CDKN1B transcripts. Of note, p27Kip1 expression may be enhanced by other pituitary TSGs,
such as E-cadherin [170] or menin [51], and by SSA in somatotrophinomas [171]. Another
member of the Cip/Kip family, p21Cip1/Waf1, is a target of p53 and induces growth arrest,
essentially at the G1/S transition but also in G2/S. It may also be induced by oncogenes such as
PTTG and Ras. The role of p21Cip1/ in tumorigenesis is complex, since it may also have anti-
apoptotic properties, depending on its subcellular localization [172]. Indeed, nuclear p21Cip1
represses the transcriptional activity of E2F1, STAT3 and c-myc, whereas cytoplasmic p21Cip1
binds to and inhibits pro-apoptotic molecules such as pro-caspase 3 and caspase 8 [172]. In the
pituitary, the best characterized effects of p21Cip1 are growth arrest and senescence. Using
double and triple knock-out mice models for pRb+/-, PTTG-/- and/or p21-/-, p21 ablation was
shown to restore tumorigenesis – induced by pRb+/- and abolished by PTTG-/- knock-out - and
accelerate S-phase entry [173]. As already reported, germline CDKN1A/ p21Cip1 mutations have
been occasionally involved in MEN1-like syndromes [66]. Nuclear 21Cip1 immunostaining has
been reported in secreting PA, especially somatotrophinomas [174,175]. Similar data were
obtained in a recent study, which also reported a frequent cytoplasmic localization in pituitary
tumours, especially NFPA and pituitary carcinomas, but not in somatotrophinomas [176].
6.2.3. PTTG
Although PTTG1 – the most abundant and widely studied member of the PTTG family,
commonly referred to as PTTG - was first identified in the rat pituitary GH4 cells, it has
important oncogenic properties in a number of additional endocrine and non-endocrine
neoplasia and cells overexpressing PTTG are tumorigenic in vivo. The biological functions of
PTTG are highly complex and derive from important functional domains among which DNA-
binding, SH3-binding and transactivating domains. Both nuclear and cytoplasmic localiza‐
tions can be observed, nuclear shuttling being enhanced by the ubiquitous PTTG-binding
protein (PBF) and by MAP kinases [177]. As a nuclear protein, PTTG has a dual role: it acts as
a global TF - enhancing gene transcription either directly through binding DNA at specific
promoter sites or indirectly through an interaction with other TFs - and as a securin protein -
inhibiting premature separation of sister chromatids during mitosis –. PTTG functions,
partners and target genes have been recently reviewed [177,178]. The securin function of PTTG
is in appearent contrast with its oncogenic properties, and the multifaceted aspects of PTTG
are illustrated by accumulating evidence for PTTG involvement in organ development, cell
proliferation, survival and/or apoptosis, according to the experimental model and conditions.
PTTG interacts with Sp1 to control progression through the G1/S phase of the cell cycle and to
suppress p21Cip1 transcription by binding its promoter. The expression of PTTG may be
increased by estrogens and GFs (EGF, FGF2), thereby creating positive feedback loops on cell
proliferation [177]. PTTG expression is cell-cycle-dependent, with protein degradation
occurring at anaphase and, as an estrogen inducible factor, varies according to the estrous cycle
in rodents. PTTG is also involved in the control of genetic stability and angiogenesis. Detailed
reviews are available on this topic [177-179]. In the normal pituitary, PTTG is expressed at low
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levels and is typically undetectable by IHC [177]. PTTG is necessary to pituitary development
and a large body of evidence supports its dual involvement in the initiation and progression
of PA [177,179]. Targeted pituitary overexpression of PTTG under the control of the α-subunit
promoter in transgenic mice induced multihormonal pituitary hyperplasia with focal gona‐
dotroph and somatotroph PA [180]. PTTG overexpression has been consistently shown to
occur at both transcriptional and protein levels in PA, though conflicting data have been
reported about its subcellular localization. Predominant cytoplasmic localization was first
reported in PA cells [177]. Subsequently, using a monoclonal antibody, nuclear PTTG immu‐
nostaining was observed in 90% of PA of different histotypes and strongly correlated with the
Ki67 labeling index (P<0.001), although the percentage of PTTG immunopositive nuclei was
highly variable from case to case [177]. PTTG expression was also found to correlate with
invasiveness in secreting PA, in particular in somatotrophinomas [177,179]. Yet, no genetic
alterations have been found to explain PTTG overexpression and epigenetic changes [179] or
miRs dysregulation [104] have been proposed.
6.2.4. HMGA proteins
The HMGA family of nuclear proteins - HMGA1a/b/c and HMGA2 - is composed of DNA-
binding molecules involved in the architecture of chromatin and modulates the transcriptional
activity of several TFs. They are widely expressed during embryogenesis, strongly down-
regulated or silenced in normal adult tissues, and commonly re-expressed in solid tumours,
including PA [181,182]. HMGAs are involved in different biological processes such as cell
proliferation, cell differentiation, DNA repair [181] and interfere with the cell cycle in different
ways. HMGA2 interacts with pRB and facilitates the expression of E2F1 target genes through
histone modifications and acetylation of E2F1 itself, thereby promoting the G1/S transition.
HMGAs also enhance the transcription of cyclin B2, which is involved in the G2/M transition.
The critical role of HMGAs in pituitary tumorigenesis has been proven by transgenic HMGA
models, which develop GH/PRL-secreting PA and additional neoplasia (eg, lipomas, fibroa‐
denomas, T-cell lymphomas). HMGA1b and HMGA2 have been recently shown to enhance
Pit1 gene transcription and interact with the Pit1 protein [183]. Overexpression of HMGA2
was reported by IHC in 39% of human PA, in particular in FSH/LH- and ACTH-secreting PA
(>60%), to a lesser extent in prolactinomas (~30%), and significantly associated with tumor
invasion [184]. In contrast, HMGA2 was not detected in the normal pituitary [184]. Similarly,
nuclear immunostaining for HMGA1 was observed in 62% of PA of all histotypes, with a
prevalence ranging from 37% in corticotrophinomas to 100% of null cell PA, but not in the
normal pituitary [185]. Overexpression of HMGA2 in prolactinomas has been explained by
gene amplification and rearrangements of the HMGA2 locus in 12q14-15, with a frequent
polysomy of chromosome 12, but this rarely occurs in NFPA [182,185]. Alternatively, overex‐
pression of HMGA genes could be explained by the down-regulation of let-7 [182] and an
additional set of miRNAs [107, 112], which enforced expression was found to decrease cell
proliferation in pituitary cells [107, 112].
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6.3. Abnormal proliferative pathways in pituitary tumours
The Raf/MEK/ERK and PI3K/Akt/mTor pathways are typically activated by GFs but crosstalks
with neuropeptide/GPCRs signalling pathways are being increasingly recognized [186].
Crosstalks between the Raf/MEK/ERK and PI3K/Akt/mTor pathways result in the modulation
of ERK1/2 activity, which is involved in the regulation of cell growth and differentiation,
depending on the cellular context, and represents an important proliferative pathway in
cancer. Secondary activation of mTOR signalling represents an important link between cell
proliferation and metabolism [187]. These pathways are essential in oncology, many drugs
have been designed to target their effector molecules at different steps [188] and similar
strategies may be of interest in selected PA [189,190].
6.3.1. The Ras/Raf/MEK/ERK pathway
The Ras/Raf/MEK/ERK pathway originates at the cell membrane with receptors for GFs or
cytokines, which activate the GTPAse Ras protein family through the coupling complex Shc/
Grb2/SOS. The active, GTP bound, form of Ras recruits Raf proteins, which in turn activate a
cascade of phosphorylations on cytoplasmic MAP kinases (MEKs and ERKs). A large number
of cytoplasmic and nuclear proteins have been recognized as ERK1/2 targets, including the
ribosomal S6 kinase (which in turns phosphorylates CREB), TFs (eg. c-myc, c-fos) and Cyclin
D1. Activation of the Ras/Raf/MEK/ERK pathway in PA may result from increased stimulation
by GFs/cytokines, overexpression or constitutive activation of their receptors, overexpression
of B-Raf [191], exceptionally H-Ras [88] or B-Raf mutations [87]. Noteworthy, overexpression
of B-Raf and a V600E mutation were found only in NFPA [87,191]. In an extensive western
blot study, an over-phosphorylation of MEK1/2 and ERK1/2 was observed in all PA histotypes,
although CyclinD1 was overexpressed in NFPA only [192]. GPCRs may activate Raf through
the cAMP/PKA or the DAG/PKC pathways and therefore induce ERK1/2 phosphorylation.
There is accumulating evidence that such mechanisms are relevant in different pituitary cells:
ERKs have been involved in CRH-induced POMC transcription in AtT20 cells [193], gender-
specific regulation of gonadotrophs by GnRH [194], GHRH induced expression of Cyclin D1
in somatotrophs [189] and the stimulation of PRL promoter activity by the Gsp oncogene in
GH4C1 cells [195]. In contrast, reduced ERK1/2 activation has been involved in SSA signalling
in somatotrophinomas [172].
6.3.2. The PI3K/Akt/mTOR pathway
The PI3K/AKT/mTOR pathway also initiates at the cell membrane in response to a variety of
GFs and hormones, including insulin. PI3K phosphorylates phosphoinositides, resulting in
the production of phosphoinositide 3-phosphate which in turn regulates the activity and
intracellular localization of a number of target proteins, among which the best characterized
is Akt (also known as Protein Kinase B/PKB). PI3K is negatively regulated by the tumour
suppressor PTEN. The activation of Akt/PKB results in a cascade of phosphorylations,
including mTOR, GSK3β, crosstalks with the Raf/MEK/ERK pathway at different levels, and
has been involved in cell proliferation and motility in a number of cancers. Moreover,
repression of the tumour suppressor Zac1 and activation of β-catenin through GSK3β are
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indirect effects of PI3K/Akt activation. The mTOR pathway is also activated by nutrients,
cellular energy levels (ATP, O2) and stress conditions; it is a major regulator of ribosomal
biogenesis and protein synthesis, in particular through the activation of the ribosomal S6
kinase p70S6K and 4EBP1, which enhances the translation of c-myc and Cyclin D1 mRNA [186].
Mutations and amplifications of the PIK3CA gene, encoding the p110 subunit of PI3K, has been
reported in a large series of PA [88]. In this study, PIK3CA mutations were present in nearly
10% of invasive PA, whereas gene amplification, associated with protein immunostaining in
a subset of cases, was found in ~30% of PA, with the highest prevalence in NFPA and no
significant correlation with tumour invasiveness. Both Akt1 and Akt2 isoforms were found
over-expressed and over-phosphorylated in PA, especially in NFPA, with no change in PTEN
expression or sequence [196]. Increased phosphorylation of Akt, mTOR and p70S6K was
reported in a genetic model of TSH-oma [197]. However, no change in mTOR and S6K
expression or phosphorylation status was observed in PA [192]. Zac1, a zinc finger TF, is widely
expressed in normal tissues, down-regulated in a variety of human neoplasia, and induces cell
cycle arrest and apoptosis, at least in part through the induction of p21Kip1 and p57Kip2 [198]. It
is involved in pituitary development and normally expressed by all pituitary cell types, but is
strongly down-regulated in NFPA, where a complete loss of expression can be observed,
especially in the null cell histotype [198]. No Zac1 mutations have been found but epigenetic
silencing is frequent and LOH at the corresponding locus (6q24-25) may occur. Interestingly,
the expression of Zac1 in somatotrophinomas is increased by SSA and correlates with the
therapeutic response [198]. Data obtained in GH3 cells indicate that this effect depends on the
inhibition of PI3K/Akt signalling [198]. Zac1 appears as an essential mediator of SSA [198] and
may be related to AIP [80].
6.4. Angiogenesis and hypoxia-pathways
Although angiogenesis is involved in the progression of many solid tumours, its pathogenetic
role in PA is still not well defined. The normal pituitary gland is already highly vascularised
and different studies on microvessel density (MVD) in PA have provided evidence for a
reduced vascularity as compared to the normal tissue. On the other hand, increased vascularity
can occur, as reported in estrogen-induced prolactinoma models and in some human pituitary
tumours [142]. Despite conflicting results about potential factors associated with an increased
vascularity (eg. age, male gender), most studies suggest that, in contrast to other solid tumours,
there is no correlation between increased vascularity and the proliferative activity of PA
[142,199]. Angiogenesis results from the balance between angiogenic and anti-angiogenic
factors and requires extracellular matrix remodelling to allow the migration of endothelial
cells. Among pituitary pro-angiogenic factors, VEGF and FGFs are the best characterized. Both
VEGF and FGF2 are upregulated by estrogens and PTTG in PA, and correlations have been
reported between the expression of PTTG and both FGF2 and VEGF-A [179].Vascular density
was also associated with PTTG expression in somatotrophinomas [179]. Estrogens down-
regulate thrombospondin, an anti-angiogenic factor also involved in TGFβ signalling and
apoptosis [125], and thrombospondin analogues have recently proven useful in the treatment
of estrogen-induced prolactinomas [200]. In contrast, with the possible exception of gonado‐
trophinomas, the endocrine-gland derived VEGF (EG-VEGF) was found to be down-regulated
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in PA [201]. Hypoxia pathways also stimulate angiogenesis, the Hypoxia-Inducible Factor
(HIF)-α being the most important TF involved in the cellular response to hypoxia. Nuclear
HIF-α immunostaining was reported in PA but not in the normal pituitary [202]. HIF-α protects
HP75 cells from apoptosis under hypoxic conditions [203] and is stabilised by RSUME, a
sumoylation factor, which is over-expressed in PA and plays an important role in VEGF-A
induction under hypoxic conditions in pituitary tumour cells [204]. Angiogenesis may favour
hemorrhage, and tumour apoplexy may occur, especially in pituitary macroadenomas.
Hemorrhagic PA were reported to express high levels of VEGF [205, 206] and high ER
concentrations [143]. Overexpression of HIF-α in MMQ cells was found to induce VEGF and
the pro-apoptotic BNIP3 gene and to promote hemorrhagic transformation in MMQ cells
xenografts [207]. TNFα was also found to promote VEGF and MMP-9 expression as well as
tumour hemorrhage in the same model [206]. Interestingly, endoglin (CD105), a marker of
endothelial proliferating cells, was found to be lower in secreting PA treated by SSA or DA
than in untreated PA, indicating that inhibition of angiogenesis contributes to their therapeutic
effect [208]. Anti-VEGF therapy (bevacizumab) has been proposed in experimental models of
estrogen-induced [209] and dopamine-resistant [210] prolactinomas, and has been successfully
used in a pituitary corticotroph carcinoma [211].
6.5. Apoptosis in pituitary tumours
As in other tissues, apoptosis is a physiological event during pituitary ontogenesis [212]. It is
also believed to contribute to pituitary plasticity and may occur in PA, either spontaneously
or in response to pharmacological treatment. Apoptosis is generally low in normal pituitaries
and in PA, but is increased in pituitary carcinomas [213]. Apoptotic cells in PA can be detected
on routine examination on the basis of their morphological changes, though they can be missed
even by experienced pathologists, so that specific assays are more suitable for the definition
of apoptotic indexes [214]. The ISEL and TUNEL assays, which are based on the visualization
of DNA breaks, can be used on paraffin-embedded sections, but should be combined with
morphological criteria to minimize artefacts [214]. Immunohistochemical detection of proteins
involved in the apoptotic process such as activated caspase 3, cleaved cytokeratins or annexin-5
are also useful. As a general rule, apoptosis can be triggered by extra-cellular signalling by Fas
ligand (FasL) or TNF interacting with “death receptors” or by endogenous signalling following
mitochondrial or DNA damage, which is able to induce apoptosis in a p53-dependent manner.
No significant relationship between p53 expression and apoptosis have been reported in PA,
with the exception of nuclear p53 in corticotrophinomas [214]. An important determinant of
apoptosis is the cellular expression of the Bcl2 family of proteins, which contains pro-apoptotic
(eg. Bax, Bad) and anti-apoptotic/pro-survival (eg. Bcl2, Bcl-XL) proteins, which can homo- o
heterodimerize and influence cell fate. Several members of the Bcl2 family are expressed in
PA, although some discrepancies have been reported about their distribution according to
tumour histotype and behaviour [213-215]. Pro-apoptotic signals may be phenotype-depend‐
ent. Fas and FasL have been observed in the rat pituitary, especially in lactotrophs and
somatotrophs, where they have been involved in the increased rate of apoptosis during
proestrous [216], although an estrogen-dependent increase in TNFα and its receptor TNFR1
have also been implicated [151]. FasL is expressed by pituitary tumour cell lines of different
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lineages and Fas signalling was found to induce an arrest in cell proliferation at G0/G1 and
apoptosis in GH3, AtT20 and MMQ cells [217]. GH3 cells also express TNFα and overexpression
of TNFα and FasL could induce apoptosis in these cells [218]. In somatotrophs, RET hetero‐
dimerizes with its co-receptor GFRα2 and induces apoptosis in vivo and in vitro [219]. Pit-1 and
p19ARF (p14ARF in humans) activation have been involved, leading to p53-induced apoptosis
[220]. RET is a dependent receptor and both RET and its ligand GDNF are normally expressed
by somatotrophs [221]. Both have also been reported in all somatotrophinomas and, to a lesser
extent, in other-secreting PA [221]. Interestingly survivin, an anti-apoptotic protein of the IAP
family, interacts with AIP, which enhances its stability in vitro and assists its mitochondrial
import [222], but RET prevents survivin from binding to AIP [223]. Although ablation of RET
induces somatotroph hyperplasia in mice [219], no mutation in c-RET has been reported in PA
yet. Either, no AIP mutant was found to disrupt AIP-survivin interaction [223]. Studies on
survivin expression in PA has lead to conflicting results [224,225]. TIM16 is a mitochondrial
protein encoded by the Magmas gene and overexpressed in the majority of PA, in particular in
corticotroph PA and cell lines, where it has been involved in cell progression and protection
from apoptotic stimuli [226]. The Pituitary Tumour Apoptosis Gene (PTAG), identified by
random PCR analysis of methylated genes in PA, was involved in bromocriptine-induced
apoptosis in AtT20 cells [227]. Pitx2, a developmental pituitary TF involved in Wnt/β-catenin
signalling, is an anti-apoptotic factor in gonadotrophs and is overexpressed in NFPA [228].
Although PTTG overexpression has been shown in different tumour cell lines to promote
apoptosis, in part through p53-mediated mechanisms, it may also inhibit the transcriptional
activity of p53 [177]. The potential role of PTTG in the control of apoptosis in pituitary cells
remains to be further clarified. Several p53-inducible genes have been involved in cell cycle
arrest and apoptosis in PA(eg. GADD45, Reprimo). Drug-induced apoptosis may be part of
the therapeutic response to SSA and DA in PA. DA may induce apoptosis in lactotrophs
through the short isoform of D2R and this effect can be sensitized by estrogens [229]. The
apoptotic response to SSA has been mainly associated with SSTR2 and SSTR3, although the
alternatively spliced variants of SSTR2 may have opposite effects [230].
6.6. Senescence
Senescence is an alternative tumour-suppressive cell faith to apoptosis in benign neoplasia. It
is characterised by an irreversible arrest in cell proliferation and accompanied by an increase
in cell cycle inhibitors such as p53, p19ARF, p21Cip1 and p16Ink4a. Because PA remain typically
benign, even in the presence of invasive features, it has been proposed that a senescence buffer
in PA cells exerts a protective effect against malignancy. This could in particular explain the
very low prevalence of GH-secreting carcinomas and NFPA. Indeed, beta-galactosidase, a
marker of senescence, was recently found overexpressed in somatotrophinomas and NFPA
[176]. Interestingly, this could be explained by different molecular mechanisms. Somatotro‐
phinomas show intranuclear p21 accumulation (possibly induced by aneuploidy and/or p53),
which is able to restrain cell proliferation [176,231]. In gonadotroph PA, which express low
nuclear p21Cip1, high levels of clusterin have been proposed to restrain cell proliferation by
triggering the CKIs p15Ink4b/p16Ink4a/p27Kip1 [232]. However, in both cases overexpression of
PTTG and DNA damage are present [231,232]. Because senescence may also be activated by
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oncogenes, as originally described for Ras, this may apply to PTTG in pituitary tumours.
Oncogene-induced senescence (OIS) is a protective mechanism against cancer which may also
involve cytokines. Due to its role in pituitary development and its frequent expression in PA,
IL6 is an attractive candidate for OIS in PA [131].
7. Pituitary carcinomas
Pituitary carcinomas represent about 0.2% of symptomatic primary pituitary tumours and
are  defined  exclusively  by  the  presence  of  metastases.  Their  prevalence  may  be  some‐
what underestimated, since metastases can be discovered post-mortem and the number of
reported  cases  has  been  significantly  increasing  during  the  last  15  years  [233-235].  The
current interest in pituitary carcinomas certainly reflects the recent improvements in their
diagnosis and therapeutic management. Their clinical characteristics have been reviewed
in details elsewhere [233-236]. Briefly, most pituitary carcinomas are secreting (>80%), with
malignant prolactinomas and corticotrophinomas being the most frequently encountered.
They usually present as recurrent invasive macroadenomas, with an increasing degree of
pharmacological resistance. Noteworthy, silent ACTH-secreting PA may become function‐
al  as  malignant  transformation  occurs.  Metastases  may  develop  in  the  central  nervous
system  (with  intracranial  and/or  spinal  localizations)  or  present  as  systemic  secondary
tumours, in particular in the bones, lungs or liver. Therefore, malignant transformation is
a  late  event,  which  typically  complicates  the  evolution  of  an  aggressive  PA,  although
exceptions  have  been  reported.  Yet,  there  is  no  specific  biological  marker  of  pituitary
carcinoma and no reliable prognostic marker of potential malignant transformation in PA.
The  primary  pituitary  tumour  often  displays  a  high  mitotic  index  and  extensive  p53
immunostaining,  the  apoptotic  index  is  typically  higher  than  in  PA,  but  none  of  these
features is invariably present and no threshold value of Ki67 or p53 immunopositivity can
be defined. Several molecular abnormalities are encountered more frequently in pituitary
carcinomas, such as chromosome gains, H-Ras mutations, overexpression of c-myc, HER2,
galectin-3,  loss  of  pRB,  p27 and menin expression [233,234].  Active research is  ongoing,
aiming  to  identify  molecular  markers  of  aggressiveness  and/or  malignancy,  which  may
differ  according to  the functional  phenotype [110,237,238].  Understanding the molecular
pathways  of  malignant  transformation  and  progression  of  pituitary  carcinomas  should
provide  new  tools  for  targeted  therapies,  as  recently  proposed  for  anti-VEGF  or  anti-
EGFR therapy [138,210,211]. In addition, there is a need for reliable predictive markers of
chemotherapy efficacy.  Temozolomide (TMZ) has  recently  proven to  be  a  very  efficient
tool  for  the  treatment  of  pituitary  carcinomas  and  highly  aggressive  PA,  in  particular
prolactinomas [239-241]. Because changes in DNA induced by alkalylating agents may be
reversed by the DNA repair enzyme O’6 methylguanine methyltransferase (MGMT), it has
been  proposed  that,  as  reported  in  glioblastomas,  MGMT  status  could  be  used  as  a
predictive  marker  of  TMZ  efficacy  in  pituitary  tumours.  Although  the  first  reports
appeared  to  confirm  such  hypothesis  [239],  recent  data  indicate  that  neither  MGMT
immunostaining  nor  MGMT  methylation  status  are  sufficiently  predictive;  instead,  a  3-
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months  clinical  trial  is  worth  regardless  of  MGMT  status  and  predictive  of  long-term
response [240,241]. In addition, the absence of correlation between MGMT gene methyla‐
tion and MGMT immunostaining argues for a complex regulation of MGMT in pituitary
tumours and further highlights the need for better prognostic tools [241, 242].
8. Conclusion
Pituitary tumours are very heterogeneous and their pathogenesis is multifactorial. During the
last two decades, increasing knowledge about factors involved in pituitary ontogenesis,
physiology and genetics have provided significant new information concerning dysregulated
pathways in pituitary tumorigenesis. The rapid development of new methodological ap‐
proaches allowing to explore hundreds of genes and proteins simultaneously (genomics/
epigenomics/proteomics) has become an essential tool to unravel new players in pituitary
tumourigenesis, although data obtained with such screening methods need to be validated on
large series of pituitary tumours and integrated with functional studies. Molecular signatures
of functional PA phenotypes are emerging and may provide significant information in terms
of pathogenesis, prognosis and treatment. The identification of reliable markers of aggres‐
siveness remains a priority for a better understanding and management of secreting PA
resistant to conventional pharmacological treatment, NFPA and pituitary carcinomas.
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